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Abstract 
 
Cytokine-based cancer therapies are commonly applied treatment strategies in oncology.  A 
prominent representative of this potent class of anti-tumor agents is interferon alpha.  Interferon is 
well known for its anti-viral and anti-proliferative activities and a potent therapeutic agent in the 
treatment of multiple myeloma, chronic myeloid leukemia (CML), hairy cell leukemia (HCL) and 
malignant melanoma. Unfortunately, the application of interferon is always accompanied by severe 
adverse side effects and shows a strong toxicological profile.  In order to overcome these obstacles 
and generate a more suitable therapeutic agent, a bispecific interferon-antibody fusion protein was 
designed. By introducing multiple point mutations, the pharmacodynamic potency of the cytokine 
was significantly improved compared to wild type interferon by increasing its affinity to the receptor 
IFNAR1. In order to prevent undesired interactions of the fusion protein during circulation in the 
periphery and consequently decrease toxic side effects, a masking antibody was connected by a 
linker sequence which led to a temporary neutralization of interferon. Local reactivation of the 
cytokine at the tumor site was initiated by the efficient cleavage of the dual MMP-9- and matriptase-
cleavable linker peptide between masking antibody and interferon with suitable turnover rates. In 
addition, enrichment of the interferon fusion protein at the tumor site was enforced by using one 
arm of the antibody for targeting the fusion protein to the multiple myeloma-associated antigen 
CD138, as successfully confirmed by confocal microscopy. The potent anti-proliferative activity of 
the cytokine in combination with a striking interferon masking effect by the linked antibody were 
shown in several cell lines originating from different oncologic indications. The promising approach 
of temporary inhibition of the cytokine in combination with tumor-selective reactivation of its 
pharmacodynamic potency holds the potential to overcome current limitations in cytokine-based 
treatment strategies and makes a broad clinical application of this extraordinary class of 
biomolecules in oncology feasible. 
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1. Introduction 
 
 
1.1 History of Interferon 
 
The story of success of interferon begins early back in 1957 when the scientists Alick Isaacs from 
the National Institute of Medical Research in London and Jean Lindenmann from the Swiss 
Academy of Medical Science launched a collaboration to investigate the interference of heat-
inactivated influenza viruses on the infectiousness of intact viruses on chorio-allantoic 
membranes of chicken embryos (Isaacs & Lindenmann, 1957). 
Prior to the above mentioned project, Lindenmann worked on red blood cells covered with heat-
inactivated virus particles and the processes taking place by challenging those cells with active 
viruses. To answer the question why the virus particles, which are fixed on the surface of the 
cells, are able to induce interactions between treated and non-treated cells, Lindenmann decided 
to cooperate with Alick Isaacs. Due to the experience of Isaacs in the field of electron microscopy 
both scientists planned to visualize the events taking place between the infected and non-
infected cells via a microscope. Unfortunately the experimental set-up turned out to be very 
challenging and the gained optical data could not be interpreted due to difficulties in 
discriminating between virus-loaded and empty cells (Pitha, 2007). 
In a new attempt the scientists used the Melbourne influenza A strain which was heat-inactivated 
at 56°C for one hour and following to that, inoculated pieces of chorio-allantoic membranes with 
the pre-treated virus at 37°C for 24 hours. Following the incubation step, the supernatant was 
replaced and membranes were washed several times with buffer to remove remaining virus 
particles from the surface. Afterwards the membranes were transferred into fresh growth 
medium and challenged with intact and non-modified influenca viruses. To evaluate the 
reproduction of viruses inside the cells, a haemagglutinin titration series was performed. From 
this experiment it was seen, that membranes which were pre-treated with heat-inactivated 
viruses, show a strong resistance against infectious viruses from the same strain. To exclude 
possible interference of the experiment by remaining virus particles from the pre-treatment step, 
a new test set-up was carried out (Isaacs & Lindenmann, 1957). 
In the final experiment chorio-allantoic membranes were treated with heat-inactivated influenza 
viruses overnight. Following the incubation, supernatants of the treated membranes were 
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collected and transferred into test tubes containing fresh membranes which have never been in 
direct contact with any virus particle. After incubation of the chorio-allantoic membranes in the 
medium derived from the previous performed virus particle treatment, infectious influenza A 
viruses were added to challenge the membranes. On the next day the viral replication rate inside 
the cells of each membrane was determined and it was observed, that the fresh membranes 
which have never been in direct contact with viral particles before, showed a surprisingly high 
and significant resistance against the attack of intact influenza viruses mediated by an inhibition 
of viral replication. A schematic drawing of this experiment can be found in figure 1 (Pitha, 2007). 
 
Figure 1: Discovery of interferon mediated viral resistance 
 
 
 
 
From their experiments, Isaacs and Lindenmann concluded that there must be a kind of 
interfering agent which mediates viral resistance between treated and non-treated cells without 
getting into close proximity. Due to this kind of “interference” they named this unknown agent 
“interferon”. At that moment both scientists had no idea that they had discovered the first 
cytokine and what tremendous impact this discovery would have on anti-viral and oncological 
indications in future times (Pitha, 2007). 
Jean Lindenmann presented the outcome of the virus induced interference between cells and the 
discovered mediating agent the first time at a meeting of the Swiss Society for Microbiology in 
Interlaken in 1957. This was the first time the cytokine interferon became apparent in scientific 
community and the kick-off for further research in the field of cytokines was initiated (Pitha, 
2007). 
Supernatants from chorio-allantoic membranes, pre-treated with 
heat-inactivated viruses, were transferred to fresh membranes 
followed by challenging them with intact influenza A viruses. 
Mediation of viral resistance by an unknown agent contained in the 
transferred supernatant was determined. (Isaacs & Lindenmann, 1957) 
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1.2 Half a century in interferon research 
 
Over the past fifty years the understanding of interferon-induced molecular mechanisms inside 
mammalian cells and the clinical application of the cytokine led to major break-troughs in anti-
viral therapies and the continuous battle against cancer. It quickly became clear that this 
paracrine and autocrine signaling molecule reveals the potential to revolutionize treatment 
strategies in infectious diseases and oncological malignancies (Borden et al., 2007). 
However, it took a long way from the discovery of interferon in 1957 to its characterization, the 
understanding of the mode of action and the clinical application of the cytokine. Before promises 
made at its discovery were able to be kept, more than a decade elapsed until new technologies in 
molecular biology raised the opportunities to investigate this cytokine in more detail. In the first 
years of interferon research scientists mainly tried to answer the question about how synthesis of 
the molecule is induced and the effects that are later on triggered in vivo. In the early 60s it was 
already shown that interferon is able to mediate viral resistance in mice and its expression is not 
limited to viral infections, but rather can be initialized by other stimulants like microbial products 
of bacteria, protozoa and virus particles  (Borden et al., 2007). 
One of the main observations in the first years of interferon research was the discovery of its anti-
proliferative activity on tumor cells, shown in several mouse models. In 1969, the group of Ion 
Gresser inoculated Balb/c and C57/B16 mice with 2000 – 3000 tumor cells and determined the 
overall survival rate of untreated mice compared to animals inoculated with interferon.  The 
experiment showed only 3.7% of the untreated mouse population survived more than 22 days. In 
contrast to that, the treatment of mice with interferon led to an increased survival rate of 98% 
within the first three weeks and an overall survival of 15% after 60 days. None of the surviving 
mice showed any signs of remaining tumor mass and all of them stayed progression free (Gresser, 
Bourali, Lévy, Fontaine-Brouty-Boyé, & Thomas, 1969). 
These promising results from early in vivo studies enforced the expectations and efforts to apply 
interferon therapy also for human beings. Already in 1977 the anti-proliferative effects of 
interferon on human derived tumor cells were able to be confirmed in non-small cell lung cancer 
(NSCLC) cell lines in vitro. In this first set of experiments, the tumor cells were treated with 
different subtypes of interferon in mono-therapy or combination with chemotherapeutic agents 
to determine the most effective treatment strategies for following clinical studies (Fujie et al., 
2011). 
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Between 1957 and the late 1970s, the application and study of this cytokine was limited by the 
low amounts and low purities of material which was isolated from cell cultures stimulated with 
viral particles. This limitation came to an end in 1980, when striking developments in molecular 
biology provided the opportunity to produce interferon in a recombinant way. One of the early 
attempts to produce the cytokine in a recombinant way was performed by the group of Shigekazu 
Nagata at the institute of molecular biology at the University of Zürich. The scientists isolated the 
12S fraction of poly-A RNA, which was coding for interferon, from interferon producing human 
leukocytes. After back-translation of the RNA by reverse transcriptase, the generated cDNA was 
cloned in a pBR322 bacterial vector plasmid. As an expression host the E.coli strain HB101 was 
chosen and transfected with plasmids containing the DNA sequence coding for interferon. 
Resulting to these efforts, a bacterial clone was identified which produced a polypeptide with an 
interferon-like biological activity in a range of 10.000 IU/g cell mass. In further analyses the 
previously gained inserts in E.coli DNA were isolated and hybridized with poly-A RNA coding for 
interferon to verify the correct incorporation of the IFN coding gene and to link the observed 
biological effects to the expression and secretion of interferon (Nagata et al., 1980). 
The new acquired possibility to produce interferon in high amounts and with a suitable grade of 
purity enforced the research in the field of cytokines. From this point of time it was possible to 
generate sufficient material for animal studies and first clinical trials in humans were launched. 
Only one year after the initial production of recombinant interferon, first investigations in cancer 
patients and multiple sclerosis patients were launched with significant treatment effects. In the 
following years different subtypes of interferon were identified and the mode of action of this 
class of cytokines was investigated in more detail. From the beginning to the middle of the 80s, 
more and more intracellular pathways, which are activated by interferon, became clear and first 
interferon stimulated genes (ISG) were reported (Borden et al., 2007). 
One of the major break-troughs in the history of interferon was the approval of recombinant 
interferon alpha 2a for clinical application in hairy cell leukemia patients in 1986. This first 
approval of a cytokine in cancer therapy has led to enormous efforts in pharmaceutical industry 
to produce high amounts of this new miracle drug. Due to extensive marketing strategies and first 
beneficial results from the clinic, people became aware of the new drug and a growing need for 
interferon aroused (Eckart, 2002). 
This vital momentum pushed interferon research to a new level and more and more clinical 
applications of this molecule were investigated in further detail. Due to positive clinical study 
results and the enforced marketing of interferon by the industry, an interferon hype was initiated 
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and this new miracle drug was published at the cover page of prestigious newspapers like The 
New York Times or the German Spiegel. Interferon was considered as the most potent drug 
against cancer and clinical trials for several oncological indications were launched. At this time in 
1990, the Federal Food and Drug Administration (FDA) approved the application of interferon also 
for anti-viral therapies against Hepatitis C (HCV). Because of the duel functionality of the cytokine 
against viral invaders and malignant cell proliferation, researchers started to study the exact 
mode of action of interferon to answer the question about how the pleiotropic effects of this 
molecule are triggered and which pathways are activated in anti-viral and anti-proliferative action  
(Borden et al., 2007). 
The decade from 1990 to the year 2000 was marked by the investigation of interferon signaling 
pathways and the identification of the main signal transducing molecules Janus activated kinase 
(JAK) and the Signal Transducers and Activators of Transcription (STAT). In addition to that, the 
three dimensional structure of interferon in complex with both receptor units was determined via 
crystal structure analysis. Following the identification of the intracellular signaling, it became clear 
that the pleiotropic mode of action of interferon cannot be explained by a single activated 
downstream cascade. New insights in the mode of action of interferon were disclosed in the end 
of the 90s by the characterization of hundreds of interferon stimulated genes (ISGs). Due to the 
activation of only one main downstream signaling pathway by interferon, the pleiotropic action of 
the cytokine can be possibly traced back to a different transcription profile of the newly 
discovered interferon-stimulated genes (Borden et al., 2007). 
The following illustration summarizes major milestones in interferon history and gives a brief 
overview about the historical development and scientific efforts in the characterization and 
clinical application of this miracle drug. 
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Figure 2: Major milestones and discoveries in fifty years of interferon research 
  
 
 
In the past 50 years of interferon research, more than 100.000 scientific papers were published 
but there are still a lot of open questions which have to be addressed. From the first observation 
of anti-viral activity of the cytokine to the characterization of a genetic transcription profile, it 
took a lot of time, effort and money, but further investigations are necessary to identify the exact 
mode of action, to control its side effect profile and to broaden the clinical application of this 
cytokine. Perhaps the second half of the interferon century will bring up new technologies to gain 
deeper insights into the field of interferon research and help to answer questions which have 
been open for more than fifty years and are still open today. 
 
1.3 Classification of interferon 
 
Since the discovery of interferon by Isaacs and Lindenmann, it became clear that there must be 
several different kinds of this cytokine which all belong to the same family of interferons. At the 
early beginning of interferon research, newly found subtypes were categorized according to the 
cell type they originated from. At these times IFN-α was known as leukocyte interferon and IFN-β 
as fibroblast IFN. Nowadays natural occurring interferon subtypes are named by their coding gene 
and the corresponding protein sequence (Bekisz, Schmeisser, Hernandez, Goldman, & Zoon, 
2004). 
The cytokine family of interferons (IFNs) is divided into two major classes, Type I and Type II 
interferons. The class of Type I interferon consists of seven different subtypes of this cytokine 
family: IFN-α, IFN-β, IFN-ω, IFN-κ, IFN-ε, IFN-δ and IFN-τ. Most prominent representatives of this 
The above shown image summarizes major milestones in interferon research. Starting 
with the discovery of the cytokine in 1957, early investigations and characterizations of 
interferon until the end of the 70s and major break-troughs and clinical studies using IFN 
from 1980 up to 2000. (Borden et al., 2007) 
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Type I interferons are IFN-α and IFN-β according to their extensive biological relevance and 
clinical trials performed with both agents. IFN-τ was only found in ruminants and giraffes but 
could not be found in human beings. Although it shows biological activity if administered to the 
human system. [Bekisz 2004] Similar to that, IFN-δ occurs only in pigs and is produced by 
trophoblasts, which form the outer layer of a blastocyst. In contrast to IFN-τ, IFN-δ does not show 
any activity in humans (Lefevre, Guillomot, D'Andrea, Battegay, & La Bonnardiere, 1998). 
IFN-κ, produced by keratinocytes, and the less well characterized IFN-ε display only limited anti-
viral and anti-proliferative activity and seem to be less important in respect to biological 
functions. From the functional point of view IFN-α with its thirteen subtypes and the single type 
IFN-β are the major mediators of viral resistance and suppressors of malignant proliferation inside 
the Type I interferon family. IFN-ω builds up the third potent anti-viral member of this cytokine 
family and is secreted by viral infected leukocytes. Interferon alpha (IFN-α) consists of thirteen 
different family members which display a close structural homogeneity. The genetic information 
for these several subtypes is located in the same region on chromosome 9 in the eukaryotic 
genome. All types of IFN-α consist of 166 amino acids with interferon alpha 2a being the 
exception with only 165 due to a deletion of a single amino acid at position 44. These different 
types of IFN-α show a strong sequential similarity in their peptide code in the range of 75 – 99%. 
The three dimensional structure of those cytokines consist of 6 alpha-helices and structural 
integrity is ensured by two disulfide bridges (Bekisz et al., 2004). 
The following table summarizes the nomenclature of the thirteen members of the IFN-α family 
and their corresponding genes. 
IFN-α protein subtype Corresponding IFN-α gene 
A 2a 
2 2b 
B2 8 
C 10 
D (Val114) 1 
F 21 
G 5 
H2 14 
I 17 
J1 7 
K 6 
4a 4a 
4b 4b 
WA 16 
1 (Ala114) 1 
   Table 1: Nomenclature of natural occurring IFN-alpha subtypes 
Summary of natural occurring interferon alpha subtypes and corresponding nomenclature 
according their protein and gene name. (Pestka & Meager, 1997) 
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Compared to the complex classification of Typ I interferons, the family of Type II interferons only 
consist of a single member termed IFN-γ. IFN-γ is mainly secreted by T-lymphocytes after 
activation by antigen binding. This Type II interferon owns a significant immune-modulatory 
capacity and evolves strong anti-viral and anti-tumor activity by the recruitment of macrophages 
and increased expression of antigen presenting MHC-Class I molecules (Pestka, Krause, & Walter, 
2004). 
Since 2002 an additional class of interferon-like molecules is known. The members of this family 
are classified as a new type of interferon because they also possess anti-viral activity and show 
similarities in the downstream signaling via the Jak-STAT pathway. This so called Type III 
interferon family contains three different interferon lambdas termed IFN-λ1, IFN-λ2 and IFN-λ3. 
These three cytokines are also known as IL-29, IL-28A and IL-28B. The genetic information for 
these types of interferon λ is located at chromosome 19 in contrast to genes for Type I and Type II 
interferons which are positioned on chromosome 9 (Kotenko et al., 2003). 
The previously mentioned interferon subclasses are distinguished from each other not only by 
their amino acid sequence and the cell type of origin, furthermore they can also bind to different 
interferon receptors with varying affinities. In case of IFN-α subtypes, the functional unit of the 
molecule acts in a monomeric fashion whereas IFN-β binds to its receptor in a dimer-like fashion. 
In contrast to INF-α, IFN-γ builds up a tetrameric structure to bind to its receptor and induce 
signal transduction. A brief overview about interferon receptors and the intra cellular signaling 
cascade will be given in the following part of the thesis (Pestka et al., 1983). 
 
1.4 The interferon receptor family and downstream signalling 
 
Each of the previously described interferon types uses its own cell surface receptor complex 
which is composed out of multiple chains. These three different kinds of cytokine receptors 
belong to the group of class II helical cytokine receptors (hCRs) and share similar structures and 
basic elements. The extracellular domain of interferon receptors is build up by tandem domains 
with a length of up to 100 amino acids. These extracellular regions contain two type III fibronectin 
domains (FBN-III) which are similar to the constant domain of an antibody. An exception in the 
number of extracellular domains is represented by the receptor unit 1 (IFNAR1) of the Type I 
interferon receptor complex which is composed of four tandem domains. The genes coding for 
Type I and Type II interferon receptors are located close to each other at chromosome 21 and 
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seem to be evolutionary conserved which indicates a possible functional connection between the 
receptors and the triggered downstream signaling cascade (de Weerd & Nguyen, 2012). 
Despite the heterologous group of Type I interferons and the differences in their peptide 
sequence, all members of this class signal through the same receptor complex of IFNAR1 and 
IFNAR2. These two receptor units differ significantly in their affinity for Type I interferons. IFNAR 
2 shows high affinity binding to IFN-α or IFN-β in a nM range whereas IFNAR 1 binds in a low 
affinity mode at µM concentrations. The common form of IFNAR2 is termed IFNAR2c which is 
composed of an intact intracellular domain connected to the two extracellular tandem domains 
via a long transmembrane region. IFNAR2c is inevitable for complete signal transduction to 
induce anti-viral and anti-proliferative activity of interferon. In addition, there are two known 
splice variants of IFNAR2. IFNAR2b consists of a short transmembrane region without an 
intracellular domain while IFNAR2a is the soluble form of the receptor lacking the 
transmembrane and the intracellular domain of IRNAR2c (de Weerd & Nguyen, 2012). 
Fully intracellular signaling in case of Type I interferons is engaged after binding of interferon to 
the receptor unit 2 (IFNAR2) followed by the formation of a ternary complex with IFNAR1. This 
formation of the IFNAR-complex is common for all members of the Type I interferon family but 
until these days it is not fully understood how the different biological activity of interferons is 
mediated via binding to the same receptor units. It was shown that the various binding affinities 
of the different interferons to their receptors, the stability of the ternary IFNAR complex and the 
total amount of receptors expressed on the cell surface can influence the expression profile of 
interferon-stimulated genes (ISGs) and the triggered biological effects (de Weerd & Nguyen, 
2012; E. Kalie, Jaitin, Podoplelova, Piehler, & Schreiber, 2008). 
The intracellular signal transduction of the IFNAR complex is mediated by the Janus activated 
kinase 1 (JAK1) located at the intracellular domain of IFNAR2 as well as tyrosine kinase 2 (Tyk2) 
coupled to IFNAR1. After formation of the ternary complex, JAK1 becomes activated via auto-
phosphorylation and triggers the recruitment of STAT (signal transducers and activators of 
transcription) molecules. Phosphorylation of the receptor-associated kinases induces the 
activation of the classical Jak/STAT pathway mediated by the phosphorylation of the signal 
transducers STAT1 and STAT2 which allows STAT homo- or heterodimerization. In case of Type I 
interferon signaling, the heterodimer composed of phosphorylated STAT1 and STAT2 forms a 
complex with IRF9 (interferon regulatory factor 9) to build up a transcription factor. This STAT1-
STAT2-IRF9 complex, also known as ISGF3 (IFN-stimulated gene factor 3), then translocates into 
the nucleus and initiates the transcription of interferon-stimulated genes (ISGs) via binding to the 
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upstream positioned interferon stimulated response elements (ISRE) which act as promoters for 
ISGs (Platanias, 2005). 
In contrast to different Type I interferons, which bind to one common receptor complex, the only 
Type II interferon IFN- γ interacts with its own cell surface receptors. This Type II receptor 
complex is composed of two subunits termed IFNGR1 and IFNGR2. Similar to the Type I interferon 
receptors, the intracellular domains of the receptor are associated with kinases to induce signal 
transduction. JAK 1 is located at the IFNGR1 subunit while IFNGR2 is associated with the JAK2. 
Both kinases trigger the phosphorylation of STAT1 molecules which then form homodimers 
before being translocated into the nucleus. Once in the nucleus, these STAT1 dimers bind to IFN-γ 
activated sites (GAS) in the genome and induce transcription of certain interferon stimulated 
genes. The formation of STAT 1 homodimers is not limited to Type II interferon receptor signaling. 
Phosphorylated STAT 1 molecules activated by Type I interferon signaling can also dimerize and 
lead to a crosstalk between Type I and Type II signal transduction (Platanias, 2005). 
 
   Figure 3: Interferon receptors and associated downstream signaling cascades 
 
 
 
Visualization of the downstream signaling cascade of Type I and Type II interferons and 
their corresponding receptors. Activation of receptor-coupled kinases (JAK1, TYK2), 
triggers phosphorylation and activation of signal transduction proteins (STAT1 and 
STAT2). In case of Type I signaling, STAT1 and STAT2 dimerize and form a transcription 
complex in combination with IRF9. Type II signaling is mediated by phosphorylated STAT1 
homodimers. After translocation of the transcription complex to the nucleus, 
transcription of interferon stimulated genes is initiated. (Platanias, 2005)  
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In addition to the main downstream signaling of interferons via the Jak/STAT pathway an 
alternative signaling pathway was identified with possible roles in the pleiotropic biological 
functions of this class of cytokines (shown in figure 4). In this alternative pathway, activated 
tyrosine kinase 2, interacting with the intracellular subunit of IFNAR1, triggers the 
phosphorylation of an adaptor protein termed CRKL. Due to this transient tyrosine 
phosphorylation of CRKL, the C3G-Rap1 signaling pathway becomes activated, leading to the 
recruitment of the small GTPase Rap 1. Rap 1 is associated with different functions in cell 
proliferation, differentiation and cell adhesion. It was shown that this small protein is able to 
mediate direct suppression of cell growth but in some circumstances can even promote 
proliferation of cells. Due to this opposed biological functions, it is believed that the mode of 
action of Rap 1 depends on the kind of stimuli triggering recruitment of C3G-Rap1 signaling. The 
activation of this alternative signaling cascade was also shown in the treatment of human cell 
lines by the Type II interferon IFN-γ which indicates a possible significant biological role in the 
anti-proliferative action of this class of cytokines (Ahmad, Alsayed, Druker, & Platanias, 1997; 
Alsayed et al., 2000). 
 
  Figure 4: Alternative interferon pathway besides classical JAK-STAT signaling 
 
Alternative signaling cascade of Type I interferons mediated via Crkl protein. 
Phosphorylation of CRKL triggers the signal transduction via C3G and the activation of 
RAP1 which strongly interacts in cell cycle control mechanisms. (Platanias, 2005) 
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1.5 Interferon in oncology practice 
 
Although the discovery of interferon has been early back in 1957, it took more than twenty years 
to produce this class of cytokines in a recombinant way to obtain sufficient amounts of material 
for performing clinical investigations. First clinical studies were conducted with crude 
formulations of cell lysates containing less than 1% interferon. The establishment of cloning 
procedures in the 1980s raised the opportunity to express large quantities of interferon with high 
grade purity and enabled the evaluation of the cytostatic, immune-modulating and antiviral 
activity of interferon in vivo. Interferon-based treatment strategies in oncologic and infectious 
diseases always deal with balancing the pharmacological effect of the cytokine and the 
prevention of adverse side effects. Due to significant unwanted responses, IFN therapies narrow 
the optimal treatment ability for physicians and side effects strongly influence patient’s quality of 
life. In oncology research, therefore understanding of the biological mode of action, the choice of 
suitable clinical indications and the management of the side effect profile and toxicities of 
Interferon play an important role to exploit the full potential of this class of cytokines (Jonasch & 
Haluska, 2001). 
Clinical indications for interferon alpha in oncology comprises several hematological cancers and 
solid tumors, including hairy cell leukemia (HCL), chronic myelogenous leukemia (CML), follicular 
lymphoma, multiple myeloma (MM), AIDS related Kaposi’s sarcoma (KS) and malignant 
melanoma. In addition to the application of interferons in oncology, IFNs play a major role in anti-
viral therapy such as chronic hepatitis B and chronic hepatitis C (Rote Liste® 2014). The following 
section summarizes the main clinical oncological indications with regard to interferon-induced 
side effects.  
The majority of interferons used in the clinic are nowadays produced in recombinant form by 
expression in eukaryotic cells, followed downstream purification methods ensuring very high 
purity. For clinical application, prominent interferon preparations are Roferon-A™ (IFN-α2a, 
Roche) and Intron-A™ (IFN-α2b, Schering-Plough Corporation). Both types of interferon alphas 
are highly similar in their amino acid sequence and differ just in one position. Besides these two 
interferon alphas, other interferon subtypes like IFN-β1a (Avonex™, Biogen Inc), an interferon 
beta type with a serine to cysteine alteration and IFN-β1b (Betaseron™, Berlex), which is 
expressed in an Escherichia coli strain, found their way into the clinic. As an alternative 
medication to Rofern-A™ and Intron-A™ in chronic hepatitis C treatment, the IFN alfacon-1 
(Infergen™, Amgen), an artificial synthesized interferon, based on the sequence comparison of 
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natural occurring IFN alphas, is approved. The only Type II interferon product on the market (IFN-
γ, Actimmune™, Genentech Inc) was approved by the U.S. Food and Drug Administration (FDA) 
for its immune-modulatory function in the treatment of chronic granulomatous disease (Jonasch 
& Haluska, 2001).  
Interferon alpha therapy in hairy cell leukemia (HCL) was approved in 1986, justified by a 
multicenter study of 64 patients performed by Harvey M. Golomb et al. in the previous years. In 
this study, patients were treated with interferon alpha 2b (Intron-A™) subcutaneously at a dosage 
of 2 x 106 U/m2, three times a week. The outcome of the study displayed complete remission (CR) 
in three patients (5%), 45 patients (70%) showed up partial response (PR) and nine patients (14%) 
a minor response. Only three of the 45 patients had no beneficial effect despite interferon 
treatment. After treatment duration of five month, hemoglobin levels and granulocyte counts re-
approached to physiological levels. The evaluation of bone marrow biopsies showed a significant 
decrease in the median hairy-cell index by half and serious viral infections during treatment were 
prevented by interferon. Due to promising first responses of interferon treatment, IFN-α2a and 
IFN-α2b are still applied in HCL therapy with treatment durations usually over two years. 
Nevertheless later studies showed that patients relapse after therapy and alternative treatment 
strategies with 2-deoxycoformycin and cladribine in hairy cell leukemia seem to be more 
beneficial (Golomb et al., 1986; Jonasch & Haluska, 2001). 
Hematologic malignancies in particular show a high treatment potential for interferon 
administration compared to solid tumors. One of these hematological indications represents 
chronic myelogenous leukemia (CML). Leading clinical evaluations of interferon in CML treatment 
were performed by the group of Talpaz et al. in the early 1980s. They evaluated the influence of 
interferon alpha 2a (Roferon-A™) on 17 patients suffering from CML, which were positive for the 
Philadelphia-Chromosome [translocation between chromosome 9 and 22, t(9;22)(q34;q11)]. In 
this study, interferon alpha 2a was administered daily intramuscularly at a dosage of 5 x 106 U/m2 
body surface. Out of 17 patients, 14 showed a response to IFN-α2a treatment. 13 patients 
displayed a complete hematologic remission (CR) and just one patient a partial remission (PR). 
The analysis of cytogenetic tests unveiled the suppression of Philadelphia-Chromosome positive 
cells in 25% of the patients responding to IFN treatment. Besides the promising outcome of the 
study, physicians had to deal with side effects triggered by interferon which led to treatment 
interruptions in two patients during the interferon therapy for 9 – 15 month (Talpaz et al., 1986). 
A comprehensive study on the anti-proliferative activity of interferon in CML was conducted by 
the Italian Cooperative Study Group on Chronic Myeloid Leukemia in 1994. To investigate the 
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potency of interferon compared to conventional chemotherapy, 322 CML patients were treated 
either with IFN-α2a (Roferon-A™) or a standard chemotherapeutic agent, hydroxyurea or 
busulfan. In the interferon treated patient population (218 patients), a karyotypic reaction was 
detectable in 30% compared to only 5% of patients treated with standard chemotherapy (104 
patients). The duration from the chronic phase of CML to a more severe blastic phase was 
significantly prolonged in the interferon treated group (72 months in the IFN-group, 45 month in 
the chemotherapy group). In addition to the decelerated disease progression, the overall survival 
of patients in the IFN-group was 21% higher than in the standard therapy group over a period of 
six years. Many other studies at that time confirmed the beneficial effect of interferon 
monotherapy compared to cytotoxic agents used in chemotherapeutic treatment of CML 
(Leukemia, 1994). 
During 1980s another effective compound against CML was investigated termed cytarabine (ara-
C). Ara-C was shown to efficiently suppress proliferation of malignant myeloid cells, when given 
via continuous infusion at low doses. The group of Kantarjian et al. performed a study on 140 
patients positive for Philadelphia-Chromosome in early chronic CML. Interferon was administered 
subcutaneously in a daily dose of 5 x 106 U/m2 body surface, in combination with a low dose 
infusion of ara-C at 10 mg/day. Due to the combination of interferon and ara-C a complete 
hematologic remission (CHR) was achieved in 92% of the treated patient population with a 
cytogentic response in 74% of responding patients. Despite the promising results of the 
combination therapy, several adverse events were reported. A significant part of the patients 
suffered from fatigue accompanied by weight loss, muscle ache, diarrhea and neurologic 
disorders. According to the outcome of the study, the combination of interferon with low-dose 
ara-C in the treatment of early-stage CML seemed to be beneficial due to the reduction of the 
applied interferon doses to a minimal but still effective level and the subsequent prevention of 
severe side effects (Kantarjian et al., 1999).   
Beside the main clinical indications of interferon in malignant hematologic diseases, several kinds 
of solid tumors can be treated efficiently. One example is the application of interferon in 
combination with other cytotoxic agents in the treatment of malignant melanoma. For growth 
inhibition of this aggressive and highly metastatic cancer type, many combination studies 
including interferon therapies were conducted. In early attempts IFN-alpha was combined with 
another cytokine, namely interleukin-2 (IL-2). Unfortunately the combination of both immune-
modulating agents did not show an additional anti-tumor effect. Other clinical trials in malignant 
melanoma combining interferon with conventional chemotherapeutics like cisplatin, dacarbacin 
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and vinblastine showed an increase in treatment efficacy which reached significant levels but 
were limited due to severe toxicities occurring by overstimulation of the immune system. A more 
beneficial application of interferon in malignant melanoma therapy was shown in clinical trials 
with an adjuvant setting, by using IFN as a follow-up therapy after initial chemotherapy. In one of 
these trials, published by Kirkwood et al.in 1994, 287 patients were treated with INFα2b (Intron-
A™) following surgical removal of the tumor mass. In the first month after surgery the maximum 
tolerable dose of interferon 20 x 106 U/m2 per day was administered intravenously. Following the 
initial high dose treatment, 10 x 106 U/m2 INFα2b were given subcutaneously three times a week 
over a period of 48 weeks. Summarizing the data generated during this study, performed by the 
Eastern Cooperative Oncology Group, the relapse-free interval of patients after surgery was 
prolonged from 1 to 1.7 years due to adjuvant interferon therapy. The overall survival of high risk 
patients was significantly increased from 2.8 to 3.8 years. The outcome of this study confirmed 
the potency of interferon in fighting against solid tumors and confirmed interferon as the first 
molecule in this indication which showed a tremendous impact on the relapse-free period and 
overall survival rate in malignant melanoma patients classified with high-risk for a relapsing 
disease (Jonasch & Haluska, 2001; Kirkwood et al., 1996). 
Interferon based cancer therapy shows significant effects in many different indications such as 
hematologic malignancies and solid tumors, e.g. malignant melanoma. Besides the promising 
activity in chronic myelogenous leukemia (CML) and hairy cell leukemia (HCL) therapy, this class 
of cytokines shows the potential to efficiently inhibit proliferation of another type of malignant 
cells of the lymphatic system. Multiple myeloma is one of the currently approved clinical 
indications (Rote Liste® 2014) for IFN-alpha and provides the capability for further investigations 
in interferon research due to a high unmet medical need in this field of oncology. According to 
this, the biology of multiple myeloma and possible interventions in the pathological development 
of this kind of lymphatic cancer will be explained in more detail in the following section. 
 
 
1.6 Interferon treatment in multiple myeloma 
 
Multiple myeloma accounts for 13% of all hematologic cancers and is characterized by an 
uncontrolled clonal expansion of plasma cells in the humoral immune system. The relatively low 
incidence rate of 5.6 cases in 100.000 persons, with a medium diagnose age of 70 years, should 
not disguise the fact that multiple myeloma is an incurable type of cancer and demonstrates a 
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high medical need for effective treatment. Current therapies comprise cytostatic and cytotoxic 
agents like the proteasome inhibitor bortezomib, the anti-angiogenic and anti-proliferative 
compounds thalidomide and its derivate lenalidomide. The application of thalidomide (formerly 
known by the trade name Contergan™) and its derivative lenalidomide in multiple myeloma is 
one of the last indication these compounds are still applied after severe side effects on newborn 
children had been detected in times when thalidomide was sold as an over the counter drug for 
its mild sedative activity. The combination of autologous stem cell transplantation and the earlier 
mentioned cytotoxic agents increased the overall survival rate of patients suffering from multiple 
myeloma (30% likelihood for a 10-year survival) (Palumbo & Anderson, 2011). 
This kind of hematologic malignancy derives from misguided plasma cells originating from pre-
germinal B-cells. Due to a genetic malfunction in terminal differentiation of B-lymphocytes into 
plasma cells, these cells gain a malignant phenotype. In more than half of the multiple myeloma 
cells, an incorporation of oncogenes in the genetic locus of the immunoglobulin heavy chain gene 
on chromosome 14 can be found.  Accompanied by the uncontrolled proliferation of a single 
plasma cell clone, the hematologic system gets flooded with enormous amounts of a type of 
pathological immunoglobulin which is termed monoclonal gammopathy. In this first stage of the 
disease, called MGUS (monoclonal gammopathy of undetermined significance), gammopathy can 
lead to a dysfunction of kidneys by clocking them with large amounts of monoclonal antibodies. 
Later on during disease progression, further genetic alterations like numerous genetic 
translocations trigger the activation of known cancer forcing genes like MYC, NRAS and KRAS 
which are involved in cell cycle control and enable increased proliferation rates. Simultaneously 
proteins which limit uncontrolled cell cycling like cyclin-dependent kinases inhibitors (CDKN2A 
and CDKN2C) become silenced. Based on the characterization and progress of genetic alterations, 
multiple myeloma can be subdivided into three stages, depending on the degree of severity and 
accompanying symptoms (Palumbo & Anderson, 2011; Smith & Yong, 2013). 
In late stage multiple myeloma, large amounts of malignant plasma cells enrich in the bone 
marrow of the limbs, hip, spinal cord and skull with dramatic consequences. After settling of 
malignant cells in the bone marrow, myeloma plasma cells bind to bone marrow stromal cells and 
stimulate the overexpression and release of cytokines like tumor necrosis factor (TNF), 
macrophage inflammatory protein (MIP) and receptor activator of nuclear factor-κB ligand 
(RANKL) into the microenvironment. The overstimulation of cells by this cytokine-cocktail triggers 
bone resorption by transformation of osteoblasts into lytic osteoclasts.  As a consequence of the 
destruction of bones, calcium from the bone marrow is released into the periphery in high 
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amounts. Hypercalcemia can be found in many multiple myeloma patients and it potentially 
correlates with the amount of tumor mass. In addition to hypercalcemia the pathologic 
syndromes in multiple myeloma comprise severe bone pain, a compression of the spinal cord and 
fractures of bones. The depletion of stem cells and hematologic progenitor cells in the bone 
marrow also lead to anemia and immune suppression due to the lack of erythrocytes and cells of 
the adaptive immune system. Because of the lack of physiological cells, bone marrow 
transplantations represent an important part of treatment strategies in many cases in order to 
reconstitute an intact cellular microenvironment and to deplete residual multiple myeloma cells 
in the bone (Oyajobi, 2007). 
Until now, there is no pharmacologically active substance known to efficiently cure this kind of 
disease. Current treatment goals mainly focus on prolonging overall survival of patients and 
reducing the suffering caused by multiple myeloma to a minimum. Interferon was first used in 
multiple myeloma treatment in 1979 with promising results, which were confirmed in many 
randomized follow up studies in combination with standard chemotherapeutic agents. In the last 
three decades numerous clinical studies in this indication were conducted, using interferon 
because of its direct anti-proliferative and immune stimulatory mode of action. A meta-analysis of 
the results of thirty randomized trials in 3948 patients was performed by E. Fritz and H. Ludwig in 
2000, summarizing the diverse outcomes of IFN therapies and demonstrating the beneficial effect 
of interferon chemotherapy on prolongation of relapse free time and overall survival of patients 
suffering from multiple myeloma. This analysis comprises the results of 17 trials performed with 
initial interferon chemotherapy treatment and thirteen trials using interferon for maintenance 
therapy after chemotherapy with proteasome inhibitors or immune stimulator agents (Fritz & 
Ludwig, 2000). 
Meta-analysis of gained data of all investigated clinical trials showed a significant improvement in 
therapeutic response of patients treated with initial interferon chemotherapy compared to 
patient groups treated with chemotherapy alone (summarized results are illustrated in figure 5). 
Interferon administration induced a 6.6% higher response rate, a prolongation of relapse free 
time up to 4.8 month and increased overall survival of 3.1 month compared to chemotherapy 
only. In case of interferon used for maintenance treatment after initial therapy with bortezomib 
or thalidomide, relapse free duration was prolonged for 4.4 month and overall survival for 7 
month. Taking into account the beneficial improvement in survival duration of multiple myeloma 
patients receiving interferon combination therapy, the rationale for interferon based treatment in 
this oncological indication seems to be validated (Fritz & Ludwig, 2000). 
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Figure 5: Meta-analysis of thirty clinical trials comparing interferon 
mono- and combination therapy 
 
 
 
  
 
1.7 Limitations of interferon in cancer therapy 
 
Besides the strong impact of the potent anti-proliferative and immune stimulating activity of 
interferon in the struggle against cancer, the medical application of this class of cytokines is 
always accompanied by serious adverse reactions which intensify the suffering of patients during 
treatment. The side-effect profile of interferon can be divided into four categories: constitutional, 
hematologic, neuropsychiatric and hepatic. Side-effects triggered by the overstimulation of an 
immune response can already occur at the beginning of the treatment and become more severe 
Results of a meta-analysis of randomized clinical trials comparing interferon 
combination therapy and chemotherapy alone. Pictured are the observed values 
for a) median progression free survival in interferon-chemotherapy, b) median 
overall survival in interferon-chemotherapy, c) median progression free survival 
in interferon maintenance treatment and d) median overall survival in interferon 
maintenance treatment. The solid line indicates observed responses in patients 
in contrast to expected values calculated by an algorithm (dotted line). (Fritz & 
Ludwig, 2000) 
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with prolonged treatment duration. Most of the observed adverse responses to interferon can, to 
some extent be related to the administered dose of the cytokine and the duration of therapy.  
From the very beginning of the treatment, patients suffer from flu like symptoms as well as from 
fevers, rigors and chills. First symptoms can already be observed within the first three to six hours 
after initial interferon administration (Jonasch & Haluska, 2001). 
After initial acute toxicity, side-effects possibly become chronic or even become more severe with 
increased treatment duration. Fatigue, representing one example of chronic side-effects, can be 
found in more than 70% of all patients during therapy. The severity of side-effects closely 
correlates with the applied dose of interferon and contribute to the dose-limiting toxicity in many 
cases. Anorexia is another major side-effect strongly influencing the health status of patients in 
more than half of all treated individuals. Until now it is not fully understood, why patients 
become anorexic and lose a lot of weight which further weakens the physiological condition of 
patients and most likely increases the development of other unwanted responses (Jonasch & 
Haluska, 2001). 
High levels of interferon in the periphery can cause neuropsychiatric disorders in patients leading 
to severe mood disorders or even depression. Anxiety syndromes and depressions can become 
worse during treatment and are most likely dose-related. The following table summarizes 
observed side-effects in numerous clinical trials with high-level interferon dosages in multiple 
myeloma therapy (Jonasch & Haluska, 2001).     
 
Figure 6: Side-effect profile of interferon determined during clinical investigations 
Observed side-effect profile of randomized clinical trials using interferon based treatment strategies in different oncological 
indications. Unwanted responses are categorized according to their mode of action and scaled depending on the degree of severity. 
(Jonasch & Haluska, 2001)  
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To increase the quality of life of cancer patients treated with interferon, used dosages of the 
cytokine have to be adapted to a minimum effective level to reduce or even prevent unwanted 
responses. Due to the severe side-effect profile, interferon in cancer therapy is often replaced by 
alternative cytotoxic agents or is only administered in case of ineffectiveness of other drugs. 
Further investigations of the exact mode of action of this anti-proliferative and immune 
modulating agent probably help to better understand why these diverse side-effects are caused 
and how interferon therapy can continue to be applied while decreasing the unfavorable 
interference into patient’s quality of life. 
 
 
1.8 Description of the proposed therapeutic attempt in interferon based  
cancer therapy 
 
To address the limitations of interferon administration in cancer therapy due to the severe side-
effect profile, the therapeutic attempt described in the following section of this thesis was 
developed by Dr. Manfred Schwaiger, Roche Diagnostics GmbH.  Clinical applications of interferon 
in oncology can be broadened in case of the reduction of unwanted responses in patients, while 
still circulating in the periphery. The use of interferon shows a significant efficacy in several 
oncological indications but optimal anti-tumor action cannot be reached in many cases because 
of low maximum-tolerable-doses of the cytokine. The aim of this work is therefore to design a 
therapeutic molecule that is able to exploit the full anti-proliferative and immune-stimulating 
potential of interferon in the battle against cancer while at the same time decreasing the severe 
side-effects that would typically come along with interferon therapy. 
One way to reach this goal is the inhibition of undesired interactions of interferon while it still 
circulates in the periphery. By designing a molecule that remains inactive during circulation, side-
effects can be reduced to a minimum level, thus, at the same time enabling the administration of 
higher dosages of interferon in cancer therapy. In order to gain a temporary inactivation of 
interferon, it can be bound by an antibody specifically directed against the subtype of the 
cytokine used for therapy. 
By binding of interferon to the complementarity determining regions (CDRs) of the antibody, it 
becomes masked and will be biologically inactive to a large extend.  
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Figure 7: Binding of interferon to masking antibody 
 
 
 
Depending on the affinity of the antibody against interferon, an equilibration of bound and non-
bound interferon with consistently changing situations would be possible. To ensure a stable 
binding of the cytokine to the masking antibody, an additional peptide linker between both 
proteins has to be introduced to the fusion protein. Due to the close steric proximity of interferon 
to the antibody created by a short linker and following the law of mass action, the majority of 
linked cytokines will be stably bound and masked by the antibodies. To enable a release of the 
interferon from the antibody at the tumor site, the used peptide linker contains cleavage motifs 
which are specifically broken up by tumor selective proteases. 
 
Figure 8: Stabilized binding of interferon to a masking antibody via a protease cleavable linker 
 
Interferon alpha 2a (IFNα2a) is bound by the anti-
IFNalpha2a-antibody called 9F3 (Genentech Inc.) Due to 
binding of the cytokine to the antibody, interferon is 
masked and mostly biologically inactive during circulation 
in the periphery. 
To ensure a stable binding of Interferon alpha 2a to its masking antibody, a peptide linker is used to connect 
both parts of the fusion protein. The used linker contains two cleavage sites for tumor associated proteases 
which are degraded after arrival of the molecule at the tumor site. 
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Inhibition of interferon during circulation and tumor selective activation of the cytokine provides 
major advantages compared to conventional interferon therapy. By ensuring interferon masking 
by an antibody, another additional attribute can be applied to the proposed fusion protein. State 
of the art technologies in antibody generation provide the possibility to produce bivalent (two 
antigen binding arms) and bispecific antibodies which are able to recognize and bind to two 
different antigens at the same time. With the help of these bispecific molecules, an additional 
targeting moiety can be introduced to the interferon fusion protein. Using one arm of the 
antibody with specificity against a tumor-associated antigen, the interferon fusion protein can be 
targeted to the tumor site and enriched in the tumor microenvironment. As a consequence of the 
enrichment of the molecule at the tumor site, pharmacodynamic properties of the fusion protein 
can be increased in combination with a reduction of unwanted responses in the periphery. The 
following figure summarizes the attributes of the designed bispecific interferon fusion protein. 
 
 
Figure 9: Summary of the proposed bispecific interferon fusion protein 
 
 
 
The proposed fusion protein is composed of one antibody arm binding and 
masking interferon, while the other antibody arm shows binding specificity 
against a surface protein expressed on tumor cells. Due to this bispecific format, 
a selective activation of the cytokine parallel to an enrichment of the molecule 
at the tumor site can be ensured. 
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For the generation of a bispecific antibody, several techniques, for example Knobs-into-Holes and 
CrossMab, need to be applied simultaneously and are describe in closer detail in the method 
section of the thesis. Fusing interferon to a human IgG1 antibody raises an additional 
improvement of the pharmacokinetic attributes of the cytokine by increasing the half-life of 
interferon from a view hours up to two weeks which is mediated by the recycling of the carrier 
antibody via a so-called FcRn-recycling mechanism. 
 
1.9 Proposed mode of action of the interferon fusion protein 
 
After intravenous administration of the interferon fusion protein, the molecule circulates 
randomly through the body and is distributed to all kind of tissues via the blood stream. Binding 
of interferon by the antibody inhibits the biological function of the cytokine to a great extent and 
should also reduce unwanted responses in healthy organs to a minimum. The clearance of 
interferon from the body via renal exclusion typically occurs very quickly, but because of the 
increased size of the fusion protein (190 kDa) above the renal exclusion limit of <70 kDa, fast 
clearance is prevented and enables the molecule to stay in the system much longer. Additional 
prolongation of half-life is achieved by the recycling mechanism of the antibody inside cells. 
Human IgG1 antibodies bind to the neonatal Fc-receptor (FcRn) and are recruited to the FcRn-
mediated recycling mechanism which leads to endosomal escape of antibodies after unspecific 
internalization in endothelia cells (Roopenian & Akilesh, 2007). 
 
Figure 10: Neonatal Fc-receptor-mediated IgG recycling mechanism 
 
 
During endocytosis, type G immunoglobulins (IgG) bind to FcRn receptors at 
an acidic pH inside the endosome. Complexes formed by IgGs and receptors 
are transported back to the surface of the cell. Endosomal escape and release 
of the antibody from the FcRn receptor is initiated by the physiological pH 
level of the blood stream. (Roopenian & Akilesh, 2007) 
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Fusion proteins which pass by the tumor site get enriched in the tumor microenvironment by 
binding of the bispecific interferon fusion protein to an antigen expressed by the tumor cells itself 
(direct targeting), or expressed by tumor-associated supporting cells (indirect targeting) like 
fibroblasts. The homing of the fusion protein at the pathologic tissue leads to an increased 
concentration of the pharmacologically active agent at the tumor site and a reduction of 
circulating interferon in the periphery. Direct targeting strategies would comprise the selection of 
an antigen expressed on the surface of cancer cells preferentially choosing a non-internalizing 
target to prevent internalization and degrading of the interferon fusion protein. 
 
Figure 11: Binding and enrichment of fusion proteins on the surface of tumor cells 
 
 
 
 
Following the binding of the interferon fusion protein to the surface of tumor cells, proteases 
cleave the peptide linker ensuring stable binding of interferon to its masking antibody. This 
peptide linker contains two specific sequences cleavable by serine proteases which are expressed 
on the surface of tumor cells or by matrix metalloproteinases secreted in the tumor 
microenvironment. After cleavage of the stabilizing linker, interferon is enabled to diffuse away 
from the binding pocket of the antibody and becomes re-activated due to the loss of the masking 
ability of the interferon binding antibody arm of the fusion protein. Depending on the 
Enrichment of an interferon fusion protein on the surface of a tumor cell due to binding of a tumor specific antigen 
(TSA). Applying a targeting moiety to the fusion protein raises the possibility for an enforced clearance of the cytokine 
out of the periphery and ensures higher levels of pharmacologically active substance at the site of the tumor.  
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concentration of interferon receptors on the tumor cell surface and the concentration of 
surrounding fusion proteins, an equilibration between antibody bound inactive interferon and 
released active interferon adjusts at the tumor site. This slow release of the active drug ensures 
the ability to maintain a stable concentration of interferon at the target site and prevents fast 
clearance of the cytokine. 
 
Figure 12: Protease-mediated cleavage of peptide linkers triggering interferon release 
 
 
 
Re-activated interferon liberated from the fusion protein is able to bind to its receptors IFNAR1 
and IFNAR2 expressed on the surface of tumor cells. Triggered by the formation of the ternary 
signaling complex composed of IFNAR2, interferon and IFNAR1, the downstream signaling 
cascade via JAK-Stat pathway becomes activated and the expression of more than 300 different 
interferon stimulated genes is initiated. Upon initiation of the interferon signaling pathways in 
cells, the activation of pro-apoptotic proteins may lead to the induction of apoptosis of the tumor 
cells. 
Serine-proteases on the tumor surface and matrix metalloproteinases secreted into the tumor 
microenvironment are able to cleave the used peptide linker which ensures a stable binding of interferon to 
its masking antibody. After cleavage, an equilibrium between bound and released interferon establishes 
which ensures a slow release of the cytokine at the tumor. 
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Figure 13: Interferon signaling pathway induces apoptosis induction in tumor cells 
 
 
 
With this new kind of therapeutic fusion protein, dual-tumor specificity is generated firstly due to 
the targeting moiety of the second antibody arm and secondly by a tumor selective activation of 
the cytokine by the linker cleavage of proteases which are expressed on the tumor surface. This 
concept of a masking and targeting antibody format provides the opportunity to apply different 
types of cytokines with anti-tumor activity in a much more secured fashion, without losing 
efficacy of molecule.  
The following sections of the thesis describe the attempts to generate and optimize the 
previously proposed interferon fusion protein and explain in more detail which obstacles had to 
be overcome to finally obtain a new anti-cancer drug with an improved safety profile.  
 
  
Interferon which diffuses away from the antibody after cleavage of the peptide linker is able to bind to 
its receptors IFNAR1 and IFNAR2 on the surface of the tumor cells.  After binding of interferon and the 
formation of the ternary receptor complex, downstream signaling via JAK-STAT-pathway becomes 
activated and leads to the induction of apoptosis in the tumor cells. 
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2. Scientific objectives  
 
The aim of the thesis was to develop a new fusion protein format which enables the inactivation 
of a cytokine during circulation in the periphery, combined with a tumor specific release and re-
activation of the pharmacologically active cytokine at the target site. This could reduce possible 
side-effects and provide the opportunity to broaden the medical application of cytokines in 
diverse diseases with a narrow therapeutic window. 
To address this purpose, human interferon alpha subtypes were fused to an antibody with an 
adjustable affinity to an appropriate type of cytokine. Due to the binding of interferon to the 
complement determining regions of the antibody (CDRs), the cytokine becomes masked and to a 
large extent biologically inactivated during circulation in the blood stream. To ensure a stable 
binding between interferon and the antibody, a protease cleavable peptide linker was applied 
which can then be cleaved by tumor specific proteases. By using new bispecific antibody formats, 
an additional targeting moiety was introduced to the fusion protein in order to increase the 
enrichment of the fusion protein at the tumor site paralleled by prolonged residence times of the 
antibody in the tumor microenvironment. Finally, pharmacological effects may be triggered by 
the cytokine released from the antibody which binds to its receptors on the tumor cell surface 
leading to the induction of tumor cell apoptosis. 
 
In this thesis following aspects were addressed: 
I. Screening for interferon responsive cell lines to determine possible clinical indications. 
 
II. Masking of human interferon alpha subtypes by binding to anti-IFNalpha2a antibody 
called 9F3 (Genentech) and modification of binding affinities by targeted point mutations 
inside the complementarity determining regions of the antibody. 
 
III. Optimization of the protease cleavable peptide linker which ensures stable binding of 
interferon to the masking antibody. Validation of different cleavage motifs of serine 
proteases and matrix metalloproteinases. 
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IV. Investigation of improved anti-proliferative actions of non-masking bivalent interferon 
fusion proteins and possible explanations for this phenomenon.  
 
V. Improvement of pharmacological parameters of interferon alpha subtypes by 
modification of binding affinities to receptor unit IFNAR1 leading to increased biological 
effects.  
 
VI. Manufacturing of a bispecific interferon fusion protein containing a tumor-associated 
targeting moiety, an optimized protease cleavable linker and mutated interferon for 
increased anti-proliferative activity. 
 
The results of this thesis will contribute to an improved knowledge in the field of interferon-based 
treatment strategies in oncology and provide new opportunities to broaden the therapeutic 
window of this anti-proliferative and immune modulatory cytokine in a wide range of oncological 
diseases. 
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3. Material 
 
 
3.1 Equipment 
 
Trade name Reference number Supplier 
 
ÄKTAexplorer 100 18-1112-41 GE Healthcare, Munich 
ÄKTAFPLC 18-1900-26 GE Healthcare, Munich 
Biacore™ T200 28964630 / 1613172 GE Healthcare, Munich 
Climo-Shaker ISF1-X ----- Kuhner, Birsfelden SZ 
Eclipse TE2000 ----- Nikon Instruments, Egg SZ 
Gel Doc™ XR+ System 170-8195 BIO-RAD Laboratories, Munich 
Heraeus BBD 6220 D 51020241 Thermo Scientific, Braunschweig 
Heraeus Multifuge X3R 75004515 Thermo Scientific, Braunschweig 
iBlot™ 1 794617 Invitrogen, Darmstadt 
Infinite® M200 NanoQuant 30016056 Tecan, Mainz 
Leica DMIL LED 383902 Leica, Bensheim 
Lumi-Imager™ F1 1300161 Roche Diagnostics, Manheim 
Microwave 700W ----- Severin, Sundern 
NanoDrop 1000™ H764 Thermo Scientific, Braunschweig 
PowerEase® 500 287000154 Invitrogen, Darmstadt 
Rocking shaker 7-0056 neoLab, Heidelberg 
Sorvall™ RC6 Plus centrifuge 46915 Thermo Scientific, Braunschweig 
Thermomixer® comfort 535525758 Eppendorf, Hamburg 
ViCell™ XR AS26138 Beckman Coulter, Krefeld 
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3.2 Chemicals and reagents 
 
Substance Reference number Supplier 
 
2-Propanol 1.09634.2500 Merck, Darmstadt 
Agarose MP 11 388 991 001 Roche Diagnostics, Manheim 
Ampicillin 10 835 242 001 Roche Diagnostics, Manheim 
ATX Ponceau S red staining 
solution 
09189-1L-F Sigma-Aldrich, Seelze  
Citric acid monohydrate 1.00244.0500 Merck, Darmstadt 
Ethanol 8.18760.2500 Merck, Darmstadt 
Ethidium bromide solution, 
10mg/mL 
161-0433 BIO-RAD Laboratories, Munich 
Hydrochloric acid 2M 1.09063.1000 Merck, Darmstadt 
L-histidine 1.04351.0100 Merck, Darmstadt 
Pen Strep 15140-122 Gibco, Life Technologies, 
Darmstadt 
Sodium chloride 1.06444.1000 Merck, Darmstadt 
Sodium hydroxide 1.06495.1000 Merck, Darmstadt 
Tris (hydroxymethyl) 
methylamine 
T/3710/60 Fisher Scientific, Reinach SZ 
Tween 20 11 330 465 001 Roche Diagnostics, Manheim 
   
   
   
   
3.3 Cytokines 
 
Name Reference number Supplier 
 
Human Interferon Alpha A 
(Alpha 2a) 
11100-1 PBL assay science 
Human Interferon Alpha H2 11145-1 PBL assay science 
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(Alpha 14) 
Human Interferon Alpha 2 
(Alpha 2b) 
11105-1 PBL assay science 
Human Interferon Alpha B2 
(Alpha 8) 
11115-1 PBL assay science 
Human Interferon Alpha J1 
(Alpha 7) 
11160-1 PBL assay science 
Human Interferon Alpha 4b 
(Alpha 4) 
11180-1 PBL assay science 
Human Interferon Alpha C 
(Alpha 10) 
11120-1 PBL assay science 
Human Interferon Alpha D 
(Alpha 1) 
11125-1 PBL assay science 
Human Interferon Alpha F 
(Alpha 21) 
11130-1 PBL assay science 
Human Interferon Alpha G 
(Alpha 5) 
11135-1 PBL assay science 
Human Interferon Alpha I 
(Alpha 17) 
11150-1 PBL assay science 
Human Interferon Alpha K 
(Alpha 6) 
11165-1 PBL assay science 
Human Interferon Alpha WA 
(Alpha 16) 
11190-1 PBL assay science 
Human Interferon Beta 1b  11420-1 PBL assay science 
   
 
 
3.4 Consumable supplies 
 
Brand name Reference number Supplier 
 
293fectin™ 12347-500 Invitrogen, Life technologies 
Darmstadt 
Dynabeads® Protein A 1000 2D Novex, Life technologies, 
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Darmstadt 
Dynabeads® Protein G 1000 4D Novex, Life technologies, 
Darmstadt 
Eppendorf Research® Plus 
pipette 
3120000 Eppendorf, Hamburg 
Eppendorf Safe-Lock tubes 0030120 Eppendorf, Hamburg 
epT.I.P.S pipette tips 
(10 µL, 200 µL, 1000µL) 
0030000 Eppendorf, Hamburg 
Falcon, serological pipets 13-675 Corning Life Sciences DL, 
Amsterdam NL 
HiLoad™16/600 -
Superdex™200pg 
28-9893-35 GE Healthcare, Munich 
HiTrap™MabSelect Xtra™ 28-4082-58 GE Healthcare, Munich 
iBlot® Gel Transfer Stacks, 
PVDF, Regular 
IB 401001 Novex, Life technologies, 
Darmstadt 
ImMedia™ Amp Agar 45-0034 Invitrogen, Life technologies 
Darmstadt 
Inoculation spreader 86.1569.001 Sarstedt, Nümbrecht 
Lumi-Light WB substrate 12 015 200 001 Roche Diagnostics, Manheim 
Microplate 96Well PS F-
Bottom 
655098 Greiner Bio One, Solingen 
MOUSE (virus free) PLASMA 
(steril) in Lithium Heparin 
D523-07 Rockland, Gilberstville US 
Nonfat dried milk powder A 0830,1000 AppliChem, Heidelberg 
NuPage® 4-12% Bis-Tris Gel NP0321 BOX Novex, Life technologies, 
Darmstadt 
Pipet tips with microcapillary 732-0508 VWR, Ismaning 
Precision Plus Protein™ Dual 
Color Standars 
161-0374 BIO-RAD Laboratories, Munich 
S.O.C medium 15544-034 Invitrogen, Life technologies 
Darmstadt 
Series S Sensor Chip CM5 BR100530 GE Healthcare, Munich 
Steritop™ 05/0703-094 Millipore, Billerica US 
VacuCap®90 PF filter unit 4628 Pall corporation, Dreieich 
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3.5 Kits 
 
Brand name Reference number Supplier 
 
Human Ab Capture Kit BR-1008-39 GE Healthcare, Munich 
peqGOLG Gel Extraction Kit 12-2501-02 Peqlab, Erlangen 
PureLink™ HiPure Plasmid 
Megaprep Kit 
K2100-08 Invitrogen, Life technologies 
Darmstadt 
Rapid DNA Dephos & Ligation 
Kit 
04 898 125 001 Roche Diagnostics, Manheim 
 
 
3.6 Detection antibody 
 
Brand name Reference number Supplier 
 
Peroxidase AffiniPure F(ab’)2 
Fragment Goat Anti-Human 
IgG, Fcγ Fragment Specific 
109-036-098 Jackson Immuno Research, Suffolk 
UK 
 
 
3.7 Enzymes 
 
Brand name Reference number Supplier 
 
BamHI-HF® R3136S New England BioLabs, Frankfurt am 
Main 
KpnI-HF® R3142S New England BioLabs, Frankfurt am 
Main 
XbaI R0145S New England BioLabs, Frankfurt am 
Main 
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3.8 Buffers 
 
Name Reference number Supplier 
 
HBS-N buffer BR100369 GE Healthcare, Munich 
NuPage® LDS sample buffer NP0007 Novex, Life technologies, 
Darmstadt 
NuPage® sample reducing 
agent 
NP0009 Novex, Life technologies, 
Darmstadt 
Phosphate buffered saline 20012-019 Gibco, Life Technologies, 
Darmstadt 
TBST buffer 12 014 939 001 Roche Diagnostics, Manheim 
 
 
3.9 Media and supplements 
 
Name Reference number Supplier 
 
Accutase™ in DPBS, 0.05% 
EDTA 
SCR005 Merck, Darmstadt 
Bovine Serum Albumin (BSA) 
Protease free 
P06-139210 Pan-Biotech, Aidenbach 
DMEM medium 41966-029 Gibco, Life Technologies, 
Darmstadt 
FreeStyle™ 293 expression 
medium 
12338-018 Gibco, Life Technologies, 
Darmstadt 
Heat inactivated FBS 10500-056 Invitrogen, Life technologies 
Darmstadt 
Leibotwitz’s L-15 medium P04-27500 Pan-Biotech, Aidenbach 
McCoy’s 5A medium 26600-023 Gibco, Life Technologies, 
Darmstadt 
MEM Eagle medium P04-08510 Pan-Biotech, Aidenbach 
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RPMI 1640 medium P04-18047 Pan-Biotech, Aidenbach 
Trypsin-EDTA 0.05% 25300-054 Gibco, Life Technologies, 
Darmstadt 
 
3.10 Eukaryotic cell lines 
 
All tumor cell lines used in this work were derived from the in-house CELLO cell bank, which was 
established and characterized by Chugai Pharmaceutical Co., a member of the Roche Group. 
 
 
3.11 Applied computer software 
 
Software Intended use 
Nikon EZ-C1  Version 3.80 Confocal microscope 
Biacore T200 Software v2.0 Biacore T200 device 
Tecan i-control™ V.3.4.2.0 Infinite® M200 NanoQuant device 
Vector NTI Advance® 11.5.0 DNA sequences management 
Prism 6 for Windows, Version 6.04 Evaluation and visualization of raw data 
UNICORN™ 5.31 Äkta HPLC device 
 
  
Methods 
 
36 
 
4. Methods 
 
4.1 Antibody design 
 
The manufacturing of a bispecific antibody on the basis of a fully human IgG1 scaffold requires 
the simultaneous application of several antibody engineering strategies. Due to the complex 
composition of a bispecific molecule out of four different antibody chains, the correct assembly of 
the two different heavy and light chains has to be ensured. Without any control of the antibody 
chain pairing, there are ten different possibilities how any of the four different chains can be 
paired with each other.  As a consequence of an uncontrolled antibody assembly, the achievable 
yield of the preferred bispecific antibody is dramatically decreased and extensive protein 
purification steps have to be applied to separate the desired antibody from the mixture of ten 
different molecules. To overcome these limitations in antibody production and to maximize the 
accessible product amount, the following antibody engineering strategies were applied for the 
generation of a bispecific interferon fusion protein. 
 
4.1.1 Knobs-into-holes 
 
The interferon fusion protein proposed in this thesis, is assembled out of two different antibody 
heavy chains, one heavy chain with specificity for human interferon alpha and another heavy 
chain specific for a tumor-associated antigen. A method to ensure the formation of heavy chain 
heterodimers of both types of heavy chains is the “knobs-into-holes” (KiH) technology, published 
by Ridgway et al., Genentech, Inc. 
The concept of this antibody engineering technology is based on the investigations of amino acid 
interactions by Francis Crick in 1952. Originally, “knobs-into-holes” was developed as a model to 
describe the interactions and steric conformations of amino acid side chains between α-helices in 
close proximity. This concept can also be applied to evaluate the interplay of amino acids 
between both heavy chains within the Fc part of an antibody. First investigations of the α-helices 
within the Fc part of a human IgG1 antibody via X-ray crystallography were conducted by Johann 
Deisenhofer in 1981, leading to the finding that dimerization of both heavy chains is mediated by 
amino acid interactions taking place in the CH3 domains of the Fc part. In contrast to that, 
glycosylated CH2 domains exclusively interact via carbohydrates. Based on these structural and 
functional results of amino acid interactions in the CH3 domains, new attempts to enforce heavy 
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chain heterodimerization via engineering of the amino acid sequence of those domains were 
launched, which has led to the development of “knobs-into-holes” technology. Using this 
technique, a “knob” is created by the exchange of a small amino acid in one heavy chain with an 
amino acid containing a large side chain. Opposite to the created “knob” and within the CH3 
domain of the second heavy chain, amino acids with large side chains are replaced by smaller 
ones to create the “hole”. After dimerization of both heavy chains containing the modifications, 
the “knob” fits into the “hole” and a stable connection between both heavy chains is forced by an 
additional introduction of two cysteine below the “knobs-into-holes” region, which form a stable 
disulfide bond (figure 14) (Deisenhofer, 1981; Ridgway, Presta, & Carter, 1996). 
 
Figure 14: "knobs into holes" modification to enforce heavy chain heterodimerization 
A so called “knob” is generated in one CH3 domain of the antibody by the replacement of threonine with tryptophan. The amino acid 
side chain of tryptophan is build up by a large indole ring which leads to steric hindrances in case of homodimerziation of two heavy 
chains containing a “knob” modification. On the second CH3 domain of the antibody, amino acids with large side chains are replace by 
amino acids with steric more favorable residues. By this replacement a “hole” is manufactured in which the “knob” of the corresponding 
heavy chain fits into. Additional stability of the interaction is enforced by the integration of a cysteine into both heavy chains to build up 
a stable disulfide bond. 
 
To generate the “knob”, threonine at position 366 within the CH3 domain of the heavy chain is 
replaced by tryptophan with a large indole side chain. In the CH3 domain of the second heavy 
chain opposite to the CH3 domain of the first heavy chain, the “hole” is constructed by the 
replacement of steric unfavorable amino acids (tyrosine at position 407, leucine at position 368 
and threonine at position 366) by amino acids with smaller side chains (valine at position 407, 
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alanine at position 368 and serine at position 366). An additional disulfide bridge is introduced by 
the incorporation of cysteine at position 354 of the knob - heavy chain and at position 349 of the 
hole - heavy chain. 
The application of this technology for generating bispecific antibodies prevents the formation of 
knob - knob - homodimers due to steric hindrances and thus, heterodimerization of two different 
heavy chains is favored. Without any engineering strategies, the four different chains of a 
bispecific antibody can be combined in ten possible ways. With the help of “knobs - into - holes” 
and the correct pairing of heavy chains, the number of possible formats is reduced down to four 
different antibodies which increase the yield of the desirable product.   
For the manufacturing of the interferon fusion protein, a “knob” is introduced in the CH3 region 
of the heavy chain binding to human interferon alpha. Amino acid modifications for the 
generation of the “hole” are applied in the heavy chain with binding specificity for the tumor-
associated antigen CD138. 
 
4.1.2 CrossMab 
 
Even by ensuring heterodimerization of two different heavy chains by KiH technology, the 
possibility for the formation of four different antibody molecules is still given. To address this 
problem and reduce the possible outcome to a single desired antibody, another engineering 
approach has to be applied to force correct light-chain/heavy-chain interactions. In the case of 
bispecific antibodies, where the main binding affinities are mediated by the complementarity 
determining regions of the heavy chains, a single type of light chain can be used which can pair 
with both types of heavy chains. Although, this so called “common light chain” approach is limited 
by a significant decrease in antigen binding affinity compared to binding mediated by heavy and 
light chain simultaneously (Schaefer et al., 2011). 
To overcome this bottleneck in the production of bispecific IgG antibodies and reduce the various 
possible combinations of heavy and light chains to a single desired molecule, Wolfgang Schäfer et 
al. combined the “knobs into holes” technology with a new methodology termed “CrossMab” to 
control additional pairing of two different light chains. By the combination of both antibody 
engineering techniques, the assembly of a single type of bispecific IgG antibody, made up of four 
different antibody chains can be ensured and achievable protein yields maximized  (Schaefer et 
al., 2011). 
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Structure analysis of the molecular architecture of an antibody and investigations of the 
heterodimerization interfaces of the variable heavy (VH), the variable light (VL), the constant 
heavy 1 (CH1) and the constant light (CL) domains led to the awareness, that the interfaces 
between these antibody domains are identical. Due to this finding the team of Schäfer et al. 
developed an engineering approach for crossing over the antibody domains between the heavy 
and the light chains. With the help of this “CrossMab” technology, VH and VL or CH1 and CL 
domains can be replaced by each other to generate artificial light and heavy chains which cannot 
pair with natural unmodified antibody chains anymore. By applying this methodology on one arm 
of the bispecific antibody, four different antibody chains are generated which can only be paired 
with the corresponding partner. The following image illustrates the simultaneous application of 
“knobs into holes” and “CrossMab” to prevent chain fail pairing when generating a bispecific 
antibody (Schaefer et al., 2011). 
 
 
 
Figure 15: Crossing over of antibody domains 
Bispecific antibodies are made up by two different heavy and light chains (A). By applying the “knobs into 
holes” technology, heterodimerization of two different heavy chains is enforced (B). For the generation of 
artificial antibody chains, which cannot be paired with wild type chains, CrossMab technology can be utilized 
by the exchange of the light chain with the VH and CH1 domain of the heavy chain (C), crossing over of 
variable regions from both antibody chains (D) or by the exchange of CH1 and Ckappa domains (E). 
 
Methods 
 
40 
 
The CrossMab technology is applied for the generation of the interferon fusion protein by 
crossing over the variable heavy (VH) and variable light (VL) domains of the antibody arm with 
binding specificity for the tumor-associated antigen CD138. The VL domain of the CD138 antibody 
arm is attached to the constant domains of the heavy chain in combination with the VH domain 
fusion to the constant kappa domain of the corresponding light chain (figure 16). 
 
Figure 16: CrossMab technology used in the interferon fusion protein 
CrossMab technology is utilized for the production of the interferon fusion protein by crossing over the 
variable domains of the heavy and light chain of the targeting antibody arm. Due to the artificial generated 
light chain, composed out of the VH and Ckappa domains, chain miss-pairing between both arms of the 
bispecific antibody is prevented. 
 
Along with the CrossMab technology used for the modification of the tumor targeting arm of the 
fusion protein, amino acid exchanges were applied at the interferon binding antibody arm to 
facilitate pairing of the interferon binding light chain with the interferon binding heavy chain. 
Natural occurring amino acids with a positive charged side chain in the CH1 domain of the heavy 
chain are replaced by amino acids with a negative charge (glutamic acid). Additional charge 
exchanges are performed in the constant kappa domain of the corresponding light chain by 
replacement of negatively charged amino acids with arginine and lysine containing positively 
charged residues (shown in figure 17). The conversion of electric charge of the heavy and light 
chains of the interferon binding antibody arm leads to an additional prevention of miss pairing 
antibody chains.  
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Figure 17:  Charge reversal of heavy and light chains 
Wild type IgG1 antibodies contain amino acids with positively charged residues in the CH1 domain 
of the heavy chain and negatively charged amino acids in the constant region of the light chain. To 
generate a charge reversal for prevention of chain miss-pairing, arginine and lysine in the CH1 
domain are replaced by glutamic acid with a negative charge. Additionally to this modification, 
negatively charged amino acids in the constant kappa domain of the light chain are replaced by 
arginine and lysine to achieve a charge reversal. 
 
 
4.1.3 HY-RF mutation 
 
Due to the application of “knobs into holes” technology, it is possible to enforce correct heavy 
chain heterodimerization by steric hindrances of the “knob”-containing chain with another heavy 
chain carrying the same point mutation, though there still is a significant likelihood for the 
formation of hole - hole - homodimers which can pair with each other without any steric 
unfavorable amino acid residues. To prevent a time consuming protein purification procedure to 
separate bispecific antibodies from the homodimers, another mutation was applied to the 
interferon fusion protein. Based on findings from Natsume et al. and a patent from the company 
Regeneron, two point mutations were established in the CH3 domain of the “hole”-heavy chain of 
the fusion protein. The applied mutations mimic a CH3 domain of a human IgG3 antibody which 
inherently is not able to bind to protein-A. By introducing two specific point mutations, the 
modified “hole”- heavy chain is able to bind to a protein-A containing chromatographic column 
which leads to the separation of hole - hole - homodimers from correctly assembled 
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heterodimeric antibodies binding to the column via the unmodified “knob”-heavy chain. The 
following alignment of sequences from a human IgG1 CH3 domain and a human IgG3 CH3 domain 
demonstrates the applied amino acid exchange from histidine and tyrosine to arginine and 
phenylalanine to introduce a IgG3 like CH3 domain in the “hole”-heavy chain of the interferon 
fusion protein (Natsume et al., 2008; Samuel Davis, 2012). 
 
 
 
Figure 18: Modification of protein-A binding capacity 
The above presented alignment of CH3 domains derived from human IgG1 and IgG3 antibodies explains the protein-A binding 
moiety and the applied modification of the CH3 domain of the interferon fusion protein. Due to the exchange of histidine and 
tyrosine to arginine and phenylalanine in the CH3 domain of the targeting antibody arm of the fusion protein, incorrectly 
assembled bispecific antibodies are not able to bind to protein-A chromatography columns anymore. 
                       
           
                                       
4.2 Cloning of expression plasmids 
 
Based on the nucleotide sequence information of human interferon alpha and the anti-interferon 
antibody 9F3 (Genentech Inc., part of the Roche Group), DNA-Sequences coding for heavy and 
light chains of the interferon fusion protein were designed in the Vector NTI Advance® 11.5.0 
Software (Invitrogen®, part of Life Technologies). Coding DNA sequences were N-terminal flanked 
by a BamHI restriction site, followed by a signal peptide (MGWSCIILFLVATATGVHS) responsible 
for extracellular secretion of the fusion protein after protein translation and post-translational 
modifications. At the C-terminus of each gene, two stop codons (TGA, TAA) were introduced in 
combination with a XbaI restriction site. Corresponding genes of interest (GOI) were synthesized 
by GeneArt® (part of Life Technologies) and delivered in a plasmid vector termed 14ACWX.  
From the obtained lyophilized vectors, 2.5 µg of each plasmid DNA were dissolved in 25 µL 
deionized DNA-free water and mixed with 5 µL CutSmart™ Buffer (10x concentration), 15 µL 
water and 2.5 µL of the DNA restriction enzymes BamHI and XbaI. After an incubation of 30 
minutes at 37°C, each sample was prepared for gel electrophoresis by the addition of 5 µL gel 
loading buffer (10x concentration). Gel electrophoresis of restricted plasmids was performed in a 
1% agarose gel at 150V for 90 minutes. Following size separation of the genes and the 14ACWX 
vectors on the gel, DNA bands were visualized via UV-light at 280 nm and inserts cut out from the 
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gel. DNA recovery was performed with the peqGOLD Gel Extraction Kit according to the suppliers 
protocol. Gained insert DNAs coding for each chain of the interferon fusion protein were cloned 
into the linearized, eukaryotic expression plasmid RB63pUC-SSKHC1 (Roche Diagnostics GmbH), 
containing a CMV promoter, eukaryotic and prokaryotic origins of replication and an ampicillin 
resistance gene, according to the protocol of the Rapid DNA Dephos & Ligation Kit (Roche 
Diagnostics GmbH). 
From each of the obtained plasmids, 200 µg of DNA were transformed into 50 µL of XL10-Gold 
ultracompetent cells (based on the E.coli strain K12) and incubated for 20 minutes on ice. After 
heat shocking the cells at 42°C for two minutes, 300 µL of S.O.C. medium (invitrogen™) were 
added, followed by an incubation step at 37°C for 45 minutes. Transformed bacteria were 
selected overnight on ampicillin containing agar plates (ImMedia™ Amp Agar, Invitrogen™) at 
37°C. Positively selected clones were picked and transferred into 5mL LB-medium containing 100 
µg/mL ampicillin and incubated for six hours in a rolling culture at 37°C. Following incubation, 
clone suspensions were expanded into 800 mL of ampicillin containing LB-medium and incubated 
overnight at 37°C. Finally, E.coli cultures were harvested via centrifugation at 6000 rpm for 30 
minutes at 4°C. After removing the LB supernatant, bacteria pellets were processed according to 
the protocol of the PureLink® HiPure Plasmid Megaprep Kit (invitrogen™) and obtained plasmid 
DNA was stored at -20°C until further use. 
 
4.3 Eukaryotic cell transfection and expression of fusion proteins 
 
For the expression of interferon fusion proteins, the human embryonic kidney cell cline HEK293F 
(invitrogen™) was utilized. Cells were cultivated in FreeStyle™ 293 expression medium at 37°C, 
80% humidity and 8.2% CO2 concentration. For maintenance of the culture, cells were split down 
to 3*10^5 cells/mL after reaching 2*10^6 cells/mL every three days. On the day before 
transfection 1*10^6 cells/mL were seeded in 1 L of FreeStyle™ 293 expression medium and 
cultivated overnight. At the following day, 3.5 mL transfection reagent (293fectin™) were added 
into 15 mL Opti-MEM®I serum free medium and pre-incubated for five minutes at room 
temperature before addition of another 15 mL of Opti-MEM®I containing plasmid DNA coding for 
the desired protein. The four different plasmids containing the genes for heavy and light chains of 
the interferon fusion protein were applied at an equal ratio up to a total amount of 1.5 µg 
DNA/mL. After incubation of plasmid DNA and transfection reagent for 20 minutes at room 
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temperature, the transfection mixture was added dropwise to 1L of HEK293F cell culture under 
continuous shaking.  
Transfected cells were cultivated for one week at 37°C in shaking culture without additional 
feeding. On day seven after transfection, the cells were harvested via centrifugation at 4750g for 
45 minutes at 4°C to separate HEK293F cells and the interferon fusion protein containing 
supernatant. After sterile filtration, the supernatant was stored at -80°C until further protein 
purification steps.  
 
4.4 Protein purification 
 
4.4.1 Protein A chromatography 
 
For the separation of correctly assembled bispecific interferon fusion proteins from the cell 
culture supernatant, protein A chromatography was applied. This type of chromatography was 
used due to natural occurring binding interactions between protein A and the CH3 domain of 
human IgG1 antibodies. To ensure endotoxin free protein purification, the Äkta Explorer device 
(GE health care) was rinsed with 0.5 M sodium hydroxide solution overnight, followed by a pH 
restoring rinse of the system with phosphate buffered saline (PBS). After installation of a 1mL 
HiTrap MabSelect Xtra protein A column (GE health care), the fusion protein containing cell 
culture supernatant was loaded onto the column at a flow rate of 0.9 mL/min overnight. On the 
following day, proteins bound to the column were washed with 10 mL PBS at a flow rate of 0.5 
mL/min to remove remaining residues derived from the supernatant.  After washing, bound 
antibodies were eluted from the protein A column via a pH shift by rinsing with citrate buffer 
(pH3) at a flow rate of 0.5 mL/min. Fractions containing eluted proteins were collected in 2mL 
aliquots followed by addition of 200 µL  Tris buffer (2M, pH9) to restore a neutral pH value. 
Aliquots were stored on ice until further purification steps. 
 
4.4.2 Size exclusion chromatography 
 
To exclude undesired dimers and aggregates of interferon fusion proteins from the monomeric 
fraction, a size exclusion chromatography was performed. Due to varying passing times of 
molecules with different molecular weights, injected samples were segregated inside the porous 
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column material and eluted at different time points, depending on their size. For the 
chromatography, the Äkta FPLC device (GE health care) with an attached HiLoad 16/60 Superdex 
200pg (GE health care) was applied. After removal of potential contaminations of the device by 
endotoxins via overnight rinsing with 0.5M sodium hydroxide, neutral pH was restored by rinsing 
the device and the enclosed separation column with histidine sodium chloride buffer (His NaCl 
buffer, pH6). Afterwards five milliliter of the protein A chromatography derived aliquots, 
containing the total amount of purified fusion proteins, were injected into the sample loop of the 
device. Size separation was performed by the injection of loaded samples into a continuous flow 
of His NaCl buffer (pH6) at a flow rate of 1mL/min, passing through the HiLoad 16/60 Superdex 
200pg column. Fractions containing aggregates, dimers and monomers of the desired protein 
were collected manually after leaving the column. Gained fractions of the monomeric protein 
were pooled and stored in aliquots at -80°C until further analysis and in-vitro characterizations of 
the bispecific molecule.   
 
4.5 Cell viability assay 
 
Evaluation of the direct anti-proliferative activity of the previously proposed interferon fusion 
protein was conducted via the CellTiter®-Glo luminescence cell viability assay (Promega). In this 
assay, cell viability is determined via cell lyses followed by the quantitation of total adenosine 
triphosphate (ATP) concentration with the help of luminescence detection. Therefore the outer 
wells of a white 96-well plate with clear bottom were filled up with 300 µL PBS/well to prevent 
boundary effects on cell viability. The remaining 60 wells were seeded with 5000 tumor cell/ well 
in a final volume of 100 µL medium/well. In case of an adherent tumor cell line, cells were 
allowed to settle down for four to six hours. Tumor cell lines growing in suspension culture were 
treated directly after seeding into 96-well plates. To determine dose response curves for the 
biological activity of fusion proteins, serial dilutions containing 8 steps of 1:10 dilutions were 
prepared, starting with 10 or 20 nM fusion protein/well down to 0.001 or 0.002 pM, in six 
replicates. Previously described concentrations of fusion proteins were added in 5 µL of PBS to 
each well containing 5000 tumor cells.  Used seeding and treatment scheme for a representative 
assay setup can be seen in the following figure. 
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Figure 19: Seeding and treatment scheme for cell viability assays 
The outer wells of a 96-well plate (blue) were filled up with PBS to prevent boundary effects. 
For each experiment 12 wells were seeded with tumor cells without any treatment (green) as a 
reverence. Serial dilutions of fusion proteins were applied to tumor cells in six replicates (light 
brown to dark brown). 
 
After addition of the fusion protein containing treatment solution, cells were incubated for 72 
hours at 37°C. To evaluate cell viability, the 96 well plate was allowed to cool down to room 
temperature before adding 100 µL CellTiter®-Glo reagent per well. Following an incubation time 
of 15 minutes, luminescence signal was then detected via an Infinite® M200 NanoQuant reader 
(Tecan). 
 
4.6 Plasma stability 
 
To control the stability of the protease cleavable peptide linker, connecting interferon to its 
masking antibody, plasma stability was evaluated via western blot. Therefore 1 µg of the 
interferon fusion protein was dissolved in 250 µL steril, virus free mouse plasma containing 
lithium heparin (Rockland Immunochemicals Inc.) and incubated for 24 hours at 37°C and 300rpm 
shacking mode. After 23 hours 50 µL of Dynabeads® protein A magnetic beads (Novex®) were 
added and allowed to catch antibodies dissolved in the mouse plasma for 60 minutes. The 
magnetic beads were separated from the murine plasma via a magnetic particle separator (SPR) 
and washed three times with 800 µL PBS. Washed beads were resuspended in 32.5 µL of 
deionized water and admixed with 12.5 µL NuPAGE® LDS sample buffer and 5 µL NuPAGE® 
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sample reducing agent. With a heating step at 70°C for 10 minutes, magnetic beads were 
separated and collected supernatants loaded on a NuPAGE® Novex® 4-12% Bis-Tris gel. Gel 
separation was performed for 35 minutes at 150V and separated protein bands were transferred 
onto a PVDF membrane by using the iBlot® western blot system according to the corresponding 
manual. The blotted membranes were blocked for one hour with 5 % skimmed milk in Tris-
buffered saline containing 0.05% Tween 20 (TBST) before further processing. Separated heavy 
chains of interferon fusion protein were stained by an overnight incubation step of the 
membrane in skimmed milk containing a 1:1000 dilution of a goat derived anti-human F(ab')₂ 
fragment coupled to peroxidase (Jackson ImmunoResearch Inc.). After removal of the staining 
solution, the membrane was washed three times with PBS. Luminescence signal was initiated via 
the addition of 3 mL Lumi-Light western blotting substrate (Roche Diagnostics GmbH) and 
detected by using a Lumi-Imager™ F1 (Roche Diagnostics GmbH). 
 
4.7 Surface plasmon resonance (SPR – Biacore) 
 
Nowadays many optical sensing methods are applied in pharmaceutical research and one of its 
most prominent representative is the surface plasmon resonance spectroscopy or shortly SPR. 
This kind of optical sensing technology detects variations in the refraction index in close proximity 
to the sensor surface, due to interactions between molecules immobilized on the surface of a 
chip and other molecules administered in solution to it. For SPR, commonly used chips are coated 
with a thin gold layer which can be modified by applying an additional layer of long-chained thiols 
or hydrogel for the covalent immobilization of biological agents which have to be investigated. 
The application of SPR for the determination of biological interactions provides a major 
advantage in contrast to alternative optical technologies due to its label-free measurement 
methodology. A SPR sensorgram generated by the detection of the refraction index delivers 
information about the kinetic rates between the tested molecules (association and dissociation) 
and gives additional information about the binding level of one interaction partner to another 
(figure 21) (Olaru, Bala, Jaffrezic-Renault, & Aboul-Enein, 2015).  
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Figure 20: Surface plasmon resonance measurement principle 
A SPR effect occurs when a beam of polarized light hits a thin metal film in the 
interface of two substances with different refractive indices. The SPR device 
detects variations of oscillating free electrons (surface plasmons) at the surface 
of the SPR chip which is triggered by the interaction of two binding partners, 
one immobilized on the chip and another one administered in solution. Due to 
the caused shift in the angle of reflected light, molecular binding events can be 
monitored and binding kinetics determined without the need of any labels 
(Cooper, 2002). 
 
Figure 21: Example and explanation of a SPR senorgram 
During the association phase, the SPR effect leads to absorption of light and a variation in the 
reflection angle over time which is detected in the sensorgram via an increase of the response rate 
(RU). A constant response is detected via the equilibrium phase of binding interactions followed by a 
decrease of the response rate during dissociation of both molecular binding partners. 
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Performed surface plasmon resonance experiments in this thesis were conducted on a Biacore 
T200 instrument (GE Healthcare). For the covalent immobilization of anti-human Fc catching 
antibodies (GE Healthcare) diluted in HBS-N coupling buffer (containing 10mM sodium acetate, 
pH 5), a gold coated CM5 sensor chip was coupled with amine according to the suppliers’ 
recommendation (GE Healthcare) and activated by an EDC/NHS mixture. After loading of the chip 
with catching antibodies, residual carboxyl groups were inactivated by rinsing with ethanolamine. 
After the preparation of the chip, three of four champers on the chip were loaded with different 
interferon fusion proteins via binding of the Fc part of the fusion protein to the immobilized 
catching antibody. Applied sample dilution buffer was manufactured by the addition of 1 mg/mL 
bovine serum albumin (BSA) to the running buffer containing PBS admixed with 0.05 % Tween 20 
(PBST). Concentrations of the fusion protein were adjusted to reach a total capture level in the 
range of 30 to 60 RU. After equilibration of the system to 37°C, serial dilutions (0.41 - 300 nM) of 
the corresponding interaction partner (human interferon alpha or recombinant CD138), dissolved 
in PBST running buffer, were injected at a flow rate of 50 µL/min with a contact time of 180 
seconds. After each injection, the system was regenerated with 30 mM MgCl2. Gained data were 
recorded and evaluated with the Biacore T200 evaluation software. 
 
4.8 Confocal microscopy 
 
Confocal microscopy represents a powerful technique to achieve high resolution images of tissue 
and cell structures even in thick specimens. Based on a process called optical sectioning, a 
focused laser light beam illuminates a diffraction-limited spot inside the sample in contrast to 
fluorescence microscopy where the whole specimen is illuminated at the same time. Within the 
limited spot of the sample, fluorescence dyes become excited and emit light. After refocusing this 
light in the objective image plane and after passing a pinhole, out-of-focus signals are removed 
and a high resolution image is created without any unwanted background signals. Due to the 
selective excitation of fluorophores in several optical sections, labelled molecules can be detected 
in different depths of the specimen without losing signal intensity. A schematic drawing of the 
light pathway used in confocal microscopy is shown by the following image. 
Methods 
 
50 
 
 
Figure 22: Scheme of the light pathway used in confocal microscopy 
Laser light which is reflected by a dichromatic mirror passes the objective lens 
and leads to the excitation of fluorophores conjugated to the molecule of 
interest within the specimen. Emitted light from the labels passes a barrier 
filter and becomes focused via a pinhole before reaching the photomultiplier 
detector. Due to the pinhole background signals are removed which leads to 
improved image resolution in contrast to conventional fluorescence 
microscopy (© Nikon microscopy).  
 
For the evaluation of the targeting moiety of the interferon fusion protein and its internalization 
rate, the protein was labelled with the fluorophore CF™568 by using the Mix-n-Stain™ antibody 
labeling kit (Biotium) according to the suppliers’ brochure. For this experiment, the CD138 
positive multiple myeloma cell lines U266B1, RPMI 8226 and NCI-H929 were used. As a negative 
control the CD138 low expressing cell lines NCI-H520 and HelaS3 were incubated with labelled 
fusion proteins. After an overnight incubation of 3*10^3 cells, seeded with standard media in a µ-
Slide (ibidi), 5 µg/mL of labeled fusion protein were added to the cells. Images of the cells were 
taken after 1 h, 3 h, 8 h, 24 h and 48 h incubation time. Confocal microscopy was conducted by 
using an Eclipse TE2000-E, D-Eclipse C1si LSM microscope (Nikon) with a 4 laser system. For the 
excitation of labelled fusion proteins, a 561nm laser was applied and emitted fluorescence was 
collected through a 580-620 nm band pass filter. Gained fluorescence signals were captured and 
visualized by using the Nikon EZ-C1 V.3.80 software. 
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5. Results 
 
The following section of the thesis summarizes results from the construction, manufacturing and 
in vitro characterization of the proposed bispecific interferon fusion protein, giving a brief 
overview of gained experimental data and explaining the rationale for this approach to overcome 
current bottlenecks in interferon based cancer therapy. 
 
 
5.1 Screening for interferon responsive cell lines 
 
To evaluate suitable clinical indications for an anti-tumor therapy based on targeted interferon, 
cell lines originating from several different tissues of the body were screened for their 
responsiveness to interferon-induced apoptosis. Goal of the performed screening was to 
determine oncologic indications in which the full potential of the targeted interferon fusion 
protein can be applied and therapeutic efficacy developed to the maximum. Due to current 
clinical indications of interferon alpha 2a, the main focus was set on multiple myeloma, soft tissue 
adenocarcinoma and malignant melanoma (figure 23). 
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Figure 23: Interferon-induced apoptosis in different cancer cell lines 
Cell lines from different oncologic indications were seeded separately in a 96 flat well plate with 
clear bottom at a density of 5000 cells / well. Cells were treated with a 1:10 serial dilution of 
interferon alpha 2a (PBL) at a maximum concentration of 10.000 IU for 72 hours. Following 
incubation, cell viability was determined by the CellTiter-Glo® luminescent assay. Each of the 
blotted values shows the detected cell death at 10.000 IU interferon/well compared to 
untreated cells. Average values were calculated on the basis of six replicates.  Screenings of 
additional cell lines of each oncologic indication were performed by Guido Werner, Roche 
Diagnostics GmbH. 
 
Treatment of tumor cell lines originating from different oncologic indications exhibited a strong 
variability in the efficacy of interferon-induced cell death.  Response rates ranged from 10 % up to 
85 % cell death after three days of stimulation with interferon alpha 2a. Moderate responses 
were seen in soft tissue carcinoma like breast adenocarcinoma (26.3 %) and lung adenocarcinoma 
(24.7 %). Promising results from the triple negative breast cancer cell lines MDA-MB468 (58 % cell 
death) and MDA-MB231 (43 % cell death) were not able to be confirmed for other tumor cell lines 
derived from the same indication. Treatment of malignant melanoma cell lines led to a slightly 
improved average response rate (29 %) compared to soft tissue adenocarcinomas. Most efficient 
induction of cell death was monitored in multiple myeloma cell lines with an average response 
rate of 49.6 %. Prominent representatives from this class of cancer type are the cell lines U266B1 
(80 % interferon-induced cell death) and RPMI 8226 (65 % interferon-induced cell death). Based 
on the previously described findings, additional screening assays were performed with ten 
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different multiple myeloma cell lines to evaluate the suitability of this indication for further 
characterizations and possible applications of a targeted bispecific interferon fusion protein 
(figure 24). Multiple myeloma cell lines were derived from the in house CELLO cell bank which 
was established and characterized by Chugai, a member of the Roche Group based in Tokyo, 
Japan.  
 
Figure 24: Interferon-induced cell death in multiple myeloma cell lines 
Cell viability assay of multiple myeloma cell lines obtained from the CELLO cell bank were seeded separately in a 96 flat well plate 
with clear bottom at a density of 5000 cells / well.  After 72 hours cell viability was determined by a CellTiter-Glo® luminescence 
assay. Blotted response rates were calculated in comparison to untreated cells. Standard deviations for each data set were 
determined based on six replicates. a) Cells were treated with a 1:10 serial dilution of 20 µM interferon alpha 2a (dots) or 10 nM of a 
non-masking antibody fused with IFN alpha 2a (triangle). b) Dose response curve of the multiple myeloma cell line U266B1 treated 
with a serial dilution of human interferon alpha 2a. c) Dose response curve showing growth stimulation triggered by IFNalpha2a in 
KMS-28BM.  Half of the shown cell viability assays were generated in close collaboration with Guido Werner, Roche Diagnostics 
GmbH. 
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Treatment of multiple myeloma cell lines with interferon alpha 2a or a non-masking fusion 
protein containing IFN alpha 2a resulted in a diverse set of cell viability responses. Six of ten 
evaluated cancer cell lines (NCI-H929, KMS-20, KMM-1, KMS-34, KHM-1B and KMS-11) 
demonstrated moderate induction of cell death up to 50 % in the presence of interferon alpha 2a 
or the corresponding antibody fusion protein. In contrast to the common anti-proliferative effect 
of interferon alpha in multiple myeloma, the tumor cell lines OPM-2 and KMS-28 BM showed 
increased cell growth rates (OPM-2: 10-13 %; KMS-28 BM: 51-54 %) in the presence of the 
cytokine or the fusion protein. Most efficient induction of cell death by interferon-mediated 
apoptosis was monitored in the cell line U266B1 (82 % cell death) and RPMI 8226 (60 % cell 
death). Evaluated interferon responsive multiple myeloma cell lines showed similar dose 
response rates in the range of 0.1 pM up to 10 nM with differences in the maximum achieved 
induction of cell death.  
 
 
5.2 Anti-proliferative effect of Type I interferons 
 
Initial interferon activity evaluations and cell viability assays were performed with interferon 
alpha 2a due to the in-house production of IFN alpha 2a (Roferon™) at the company Roche 
Diagnostics GmbH and approved oncologic indications for this type of cytokine. The family of 
Type I interferons consists of 13 naturally occurring IFN alpha subtypes with differences in their 
anti-proliferative potency. To evaluate the anti-proliferative activity of each IFN subtype and 
determine the most suitable cytokine for an antibody fusion protein, all 13 wild type interferon 
alphas, an artificial murine and human cross-reactive IFN (universal IFN) and IFN beta 1b were 
tested in a cell viability assay on the multiple myeloma cell line U266B1 (figure 25). 
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Figure 25: Efficacy screening of human IFN alpha subtypes 
Cells from the multiple myeloma cell line U266B1 were seeded separately in a 96 flat well plate with clear bottom at a density of 5000 
cells / well and treated with a 1:10 serial dilution of human IFN alpha 2a with a maximum concentration of 10.000 IU. Cell viability was 
determined by a CellTiter-Glo® luminescence assay after 72 hours. Maximum achieved growth inhibition values, compared to 
untreated cells, are shown in the graph. Standard deviations were calculated on the basis of six replicates. Except treatment of cells 
with IFN alpha 2a, IFN alpha H2 and universal IFN alpha, screenings were performed in collaboration with Guido Werner, Roche 
Diagnostics GmbH.  
Treatment of U266B1 multiple myeloma cells with members of the interferon alpha family 
resulted in various anti-proliferative response rates, in the range of 12.6 % to 73.8 % cell death. 
Despite the overall high response rate of U266B1 to interferon alpha subtypes, treatment with 
IFN alpha A (12.6 % cell death) and IFN alpha G (no clear response) showed low or no detectable 
induction of cell death. Compared to the clinical approved treatment of multiple myeloma with 
interferon alpha 2a, additional members of Typ I interferon alphas showed enhanced anti-
proliferative activity. Especially treatment of U266B1 cells with 10.000 IU of IFNαB2 (73.8 %), 
IFNαH2 (68.6 %), universal type IFN alpha (73.8 %) and IFNαWA (71.1 %) resulted in an increased 
pro-apoptotic effect compared to IFNα2a (57.6 %). As a result of the performed cell viability 
assays, potent candidates for interferon antibody fusion proteins were identified, like IFNαH2 and 
universal type IFN.  
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5.3 Improvement of pharmacodynamics parameters of interferon 
 
Previously described cell viability assays revealed differences in the anti-proliferative potency of 
natural occurring interferon alpha subtypes on cancer cells. It is known that all members of the 
Typ I interferon family bind to a common receptor (IFNAR) on the surface of cells and mediate 
their biological effect via the same downstream signaling cascade. According to findings from 
Piehler et al, differences in the anti-proliferative activity of interferon subtypes can probably be 
explained by varying affinities of interferon alphas to the interferon receptor unit 1 (IFNAR1) 
(Piehler, Thomas, Garcia, & Schreiber, 2012). To investigate the correlation between the affinity 
of interferon alpha to IFNAR1, a 3D modelling approach was performed and biological effects 
shown by in vitro assays.   
 
 
Figure 26: Receptor affinity-mediated increase of anti-proliferative effects 
A 3D computer modelling approach reveals relevant amino acid interactions between human IFN alpha 2a and its corresponding 
receptor unit IFNAR1 (a). Interferon alpha H2 displays an exchange of threonine to isoleucine at position 86 compared to interferon 
alpha 2a (b). Cell viability assays of human IFN alpha 2a and human IFN alpha H2 on the multiple myeloma cell line U266B1 (c). Dose 
response curves were determined by treatment of 5000 cells / well in a 96 flat well plate with serial dilutions of interferon, containing 
a maximum concentration of 10 nM. Standard deviations were calculated based on six replicates. Differences in the anti-proliferative 
response were confirmed in several tumor cell lines of different oncologic indications, like breast adenocarcinoma, pancreatic 
carcinoma and ovarian cancer (data not shown). 3 D modelling of biomolecules was conducted by Dr. Guy Georges, Roche Diagnostics 
GmbH. 
 
Affinity-mediating amino acids in the binding region of interferon alpha to the interferon receptor 
unit 1 were identified via a 3D modelling approach based on open source crystallographic data. In 
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case of interferon alpha 2a, threonine at position 86 of the molecule was identified as key player 
in the interaction between the cytokine and its receptor. In contrast to IFN alpha 2a, interferon 
alpha H2 possesses an exchange of threonine to isoleucine at position 86 (Thr 86 Ile). A cell 
viability assay performed with the multiple myeloma cell line U266B1 revealed major differences 
in the anti-proliferative potency of both IFN alpha subtypes. Significant differences were seen in 
the half maximum inhibitory concentration (IC50) of the cytokines. Based on the evaluated dose 
response curves, an IC50 value of 146.6 pM for IFN alpha 2a and 5.87 pM for IFN alpha H2 was 
determined. 
 
The company Teva GmbH presented data of an interferon efficacy study on multiple myeloma 
patient-derived bone marrow at the 6th World ADC Summit, San Diego 2014 (figure 27).  
 
Figure 27:  IFN efficacy study in MM patient-derived bone marrow 
 
Presented data showed that effective treatment of multiple myeloma patients with interferon 
alpha would require IFN doses above the maximum tolerable dose of the cytokine. One way to 
overcome this bottleneck in interferon-based treatment strategies is the improvement of the 
pharmacodynamics potency of interferon. To address this task, previously gained knowledge 
about the differences in the anti-proliferative potency of IFN alpha 2a and IFN alpha H2 was used 
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to further investigate the interaction between interferon and its receptor. Based on the 
identification of the important receptor interaction capability of threonine at position 86 of 
interferon alpha, further point mutations were determined for a potential enhancement of this 
effect (figure 28). 
 
Figure 28: Affinity maturation within the IFN/IFNAR2 interaction domain 
Threonine at position 86 of wild type human interferon alpha 2a was replaced by point-mutations to histidine (a), arginine (b) and 
leucine (c). Antibody fusion proteins containing point mutated interferon were tested in a 1:10 serial dilution, starting at 10 nM, on 
the multiple myeloma cell line U266B1 (d). Cell viability was determined by a CellTiter-Glo® luminescence assay after 72 hours and 
standard deviations calculated based on six replicates. 3 D modelling of biomolecules was conducted by Dr. Guy Georges, Roche 
Diagnostics GmbH. 
 
Table 2: IC 50 values of IFN point mutations 
IFN alpha 2a variations IC 50  [pM] 
wild type 415.0 
Thr 86 Leu mutation ~ 7.276e+006 
Thr 86 Arg mutation 415.6 
Thr 86 His mutation 173.0 
 
Interferon fusion proteins containing interferon alpha 2a with an exchange of threonine at 
position 86 to arginine (green dose response curve) and leucine (orange dose response curve) 
showed a decreased anti-proliferative potency compared to an unmodified variant (black dose 
response curve). Replacement of threonine at position 86 to histidine has led to a significant 
improvement of the pharmacodynamic potency of the fusion protein (red dose response curve) 
(figure 28). Due to the exchange of threonine 86 to histidine, it was possible to reduce the IC50 
value of the wild type IFN fusion protein (415 pM) by more than half (173 pM). 
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5.3.1 Combined mutations for maximum IFNAR1 affinity 
 
Similar improvements in the modifications of the interaction between interferon alpha and the 
corresponding receptor unit 1 were achieved by the group of Gideon Schreiber at the Weizmann 
Institute, Israel (Eyal Kalie, Jaitin, Abramovich, & Schreiber, 2007). The outcome of a randomized 
mutagenesis of interferon and affinity screening against IFNAR1 has led to the discovery of three 
point mutations termed YNS mutation which mediate an enhanced affinity of interferon to 
IFNAR1 and trigger an increased anti-proliferative effect of the cytokine. Due to these findings it 
was tried to validate this data in-house and generate an interferon fusion protein containing IFN 
with YNS mutations. To investigate the potential improvement of the pharmacologic potency of 
interferon by applying the previously proposed Thr 86 His mutation in combination with YNS 
mutations, additional fusion proteins were generated and tested on the ovarian cancer cell line 
OVCAR-3 (figure 29). 
 
Figure 29: Stepwise improvement of the pharmacodynamic efficacy of interferon alpha 
Induction of cell death was monitored on the interferon sensitive ovarian cancer cell line OVCAR-3 after stimulation with serial 
dilutions of interferon alpha 2a (orange curve) [20nM], an antibody fusion protein including wild type IFN alpha 2a (black line) [10nM], 
and fusion proteins with IFN alpha 2a containing a Thr86His mutation (green line) [10nM], a YNS mutation (blue line) [10nM] 
published by Schreiber et al. and a combination of Thr86His and YNS mutations (red line) [10nM]. Cell line response was evaluated by 
a CellTiter-Glo® luminescence assay after 72 hours. Each treatment was performed and values calculated based on six replicates. 
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Table 3: Potency of IFN alpha 2a mutations 
Anti-proliferative agent IC 50  [pM] 
IFN alpha 2a, wild type 613.2 
Fusion protein containing IFN alpha 2a, wild type 415.0 
Fusion protein containing IFN alpha 2a, Thr 86 His mutation 173.0 
Fusion protein containing IFN alpha 2a, YNS mutation 41.43 
Fusion protein containing IFN alpha 2a, Thr 86 His + YNS mutation 24.24 
 
 
Treatment of OVCAR-3 cells with interferon alpha 2a and the corresponding interferon fusion 
protein resulted in similar anti-proliferate effects. Application of a Thr 86 His mutation in 
interferon alpha has led to an improvement of the pharmacological potency of the fusion protein 
by a factor of 2.4 (green curve). A significant shift in the potency of the fusion protein was 
achieved by the implementation of YNS mutations into to cytokine (blue curve). Compared to the 
interferon fusion protein containing wild type interferon alpha 2a, a tenfold reduction in the IC50 
value (415 pM to 41.43 pM) was determined. Although YNS mutations trigger a potent anti-
proliferative effect, the combination of YNS mutations and the investigated Thr 86 His mutations 
showed the most effective induction of cell death in the ovarian cancer cell line OVCAR-3. 
A significant improvement of the anti-proliferative action by the implementation of the Thr 86 His 
and the YNS mutations was shown in fusion proteins containing interferon alpha 2a. Previously 
presented data (figure 26) revealed an enhanced potency of wild type interferon alpha H2 
compared to IFN alpha 2a. To evaluate the effect of the found point mutations on a more potent 
interferon alpha subtype, fusion proteins were generated containing interferon alpha H2 and 
variants with the above mentioned point mutations. It was tried to enhance the potency of IFN 
alpha H2 to generate an artificial interferon alpha which exhibits maximized anti-proliferative 
efficacy to achieve high response rates in oncologic indications at minimal serum levels (figure 
30). 
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Figure 30: Potency enhancing mutations in IFN alpha 2a compared to IFN alpha H2 
Affinity increasing point mutations, YNS and Thr86His were implemented in fusion proteins containing human IFN alpha 2a or IFN 
alpha H2. Multiple myeloma cell line U266B1 was seeded at a density of 5000 cells / well in a 96 flat well plate and treated with serial 
dilutions of both wild type interferons [20nM] and the corresponding fusion proteins [10nM] containing modified interferon variants. 
After 72 hours cell viability was determined by performing a CellTiter-Glo® luminescence assay. Blotted values display the difference in 
cell viability compared to untreated cells. Standard deviations were evaluated based on six replicates.   
 
Table 4: IC50 values of IFN alpha H2 mutants 
Interferon fusion protein IC 50  [pM] 
Fusion protein containing IFN alpha 2a, wild type 4.81 
Fusion protein containing IFN alpha 2a, Thr 86 His + YNS mutation 1.07 
Fusion protein containing IFN alpha H2, wild type 0.94 
Fusion protein containing IFN alpha H2, Thr 86 His + YNS mutation 0.67 
 
The implementation of Thr 86 His and YNS mutations in interferon alpha 2a has triggered a 
remarkable shift in the potency of the cytokine (green curve) compared to wild type interferon 
alpha 2a (black curve). An interferon fusion protein containing wild type IFN alpha H2 (blue curve) 
displayed a similar anti-proliferative potency than fusion proteins with IFN alpha 2a with affinity 
enhancing mutations. Modification of IFN alpha H2 by applying Thr 86 His and YNS mutations (red 
curve) has led to a slight improvement in the apoptosis induction capability of the fusion protein 
(figure 30). According to these results it was possible to improve the potency of wild type IFN 
alpha 2a by specific point mutations to a similar level than IFN alpha H2. Additional modifications 
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of the affinity of IFN alpha H2 against IFNAR1 resulted only in minor improvements of the anti-
proliferative action compared to wild type IFN alpha H2. The comparison of IC50 values of the 
tested interferon variants (table 4) revealed fusion proteins containing IFN alpha H2 with Thr 86 
His and YNS mutations as the most potent anti-proliferative constructs. 
To compare the previously presented potency (figure 30) of the interferon fusion protein with 
conventional treatment strategies in oncology, the multiple myeloma cell line U266B1 was 
treated with several cytotoxic or cytostatic compounds as well as with the interferon fusion 
protein containing point mutated IFN alpha 2a (figure 31). The used cell line is known for its 
robustness and high resistance against chemotherapeutic agents. Due to the characteristics of 
this U226B1 cancer cells and the target indication for interferon fusion proteins, this multiple 
myeloma cell line was chosen for the performed comparison. 
 
 
Figure 31: Outstanding IFN potency compared to standard of care treatment 
Cell viability was determined after treatment of the multiple myeloma cell line U266B1 with standard of care proteasome inhibitor 
bortezomib, various cytostatic agents and the targeted interferon fusion protein. Serial dilutions of each inhibitor were administered 
to 5000 cells / well for 72 hours. Final read out was performed by a CellTiter-Glo® luminescence assay. Treatment of U266B1 cells with 
cytotoxic agents was performed by Guido Werner, Roche Diagnostics GmbH due to safety reasons. 
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Table 5: Potency of cytostatic compounds 
Cytostatic compound IC 50  [pM] 
Targeted interferon fusion protein 0.69 
Bortezomib 1.03e+003 
Thapsigargin 4.0e+003 
α-Amanitin 9.7e+004 
Doxorubicin 2.47e+005 
Vincristin 9.14e+005 
Melphalan 6.27e+007 
MMAE 2,84e+008 
 
Treatment of U266B1 suspension cells with the DNA alkylating compound Melphalan and the 
anti-mytotic drug MMAE resulted in weak responses with IC50 values in micromolar range. 
Moderate anti-proliferative effects were determined via the inhibition of the multiple myeloma 
cell line with serial dilutions of the anti-mytotic drug Vincristin, the DNA intercalating agent 
Doxorubicin and the DNA alkylating compound Melphalan in a nanomolar IC50 range. Although 
the sarco/endoplasmatic reticulum Ca2+ ATPase inhibitor Thapsigargin showed a potent anti-
proliferative acivity in a low nanomolar range, apoptosis was merely incuced in 67.76 % of the 
treated cells. Treament of U266B1 cells with the standard of care therapy in multiple myleoma, 
Bortezomib (proteasome inhibitor), resulted in a 99.35 % killing rate at an IC50 value of 1.03 µM. 
In contrast to Bortezomib, the application of serial dilutions of the point mutated interferon 
fusion protein has triggered an apoptosis induction of 89.56 % with an IC50 value of 0.69 pM. Due 
to the anti-proliferative actions of Bortezomib and the IFN fusion protein, the antibody cytokine 
fusion protein showed an improvement in therapeutic potency by more than a factor of 1000 
compared to standard of care treatment. 
 
 
5.4 Masking of interferon 
 
The following part of the thesis deals with attempts to temporary inhibit the activity of interferon 
by masking the cytokine with an antibody. Interferon therapy in oncologic indications is 
accompanied by unspecific interactions in the body, leading to severe side effects (Jonasch & 
Haluska, 2001) and a reduction in the patient’s quality of life. Due to these unwanted 
interactions, maximum tolerable serum concentrations of interferon are often below the 
necessary therapeutic level. To address this limitation in interferon based cancer therapy and 
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possibly broaden the clinical applicability in oncology, a masking attempt of the cytokine was 
investigated.  
To bind interferon and temporary inactivate the cytokine, the anti-interferon alpha 2a antibody 
termed 9F3 (Genentech Inc.) was used to generate an interferon fusion protein. Due to a high 
affinity of the 9F3 antibody to IFN alpha 2a in a range of 25 pM, the antibody seemed to be 
suitable for an efficient masking and inactivation of the cytokine. The proposed mode of action of 
the antibody interferon fusion protein requires a masking of the cytokine during circulation in the 
periphery and a release and reactivation of interferon after cleavage of the peptide linker at the 
tumor site. Because of the very high affinity of the 9F3 antibody to IFN alpha 2a, it was possible to 
establish an efficient masking but without the possibility of a release of the cytokine. To enable 
the diffusion of interferon away from the antibody after cleavage of the peptide linker, it was 
necessary to reduce the affinity of the antibody to a level at which sufficient inactivation of the 
cytokine takes place in combination with a possible release of it at the target site. 
For the reduction of the affinity of the 9F3 antibody, a 3D modelling approach was used to 
determine amino acids in the CDR region in the light and heavy chain of the antibody which 
mainly mediate binding of the antibody to interferon alpha 2a. As a result of this investigation, 
two amino acids in the heavy chain and three amino acids in the light chain were identified to be 
key players in the interaction between the antibody and the cytokine. Specific point mutations of 
the previously described position to amino acids with non-reactive side chains were performed to 
achieve a reduced affinity of the antibody against IFN alpha 2a with simultaneous maintaining of 
its masking capability. Efficacy of the performed affinity modulating mutations were evaluated in 
the multiple myeloma cell line U266B1 (figure 32). 
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Figure 32: Masking and temporary inactivation of interferon 
a) Evaluation of the masking ability of the anti-IFN alpha 2a antibody 9F3 and its modified versions. The multiple myeloma cell line 
U266B1 was treated either with human interferon alpha 2a [10.000 IU/mL] as single agent or in combination with inactivating 
antibodies, containing specific point mutations for modified masking abilities. A ratio of IFN : masking antibody of 2 : 1 was used. 
Masking efficiency was determined by the detection of interferon activity in combination with its masking antibody compared to cells 
treated with IFN as monotherapy by a CellTiter-Glo® luminescence assay. Blotted values and calculated standard deviations are based 
on six replicates. b) Binding of Interferon alpha 2a to its masking antibody 9F3. c) Masking and temporary inactivation of the cytokine 
by the antibody. d) Release and reactivation of interferon due to reduced antibody affinity. 3 D modelling of biomolecules was 
conducted by Dr. Guy Georges, Roche Diagnostics GmbH. 
 
In the performed assay, treatment of U266B1 with wild type interferon alpha 2a without any 
masking antibody has led to a reduction of cell viability of 71.37 % compared to untreated cells. 
Addition of anti-IFN alpha 2a antibody 9F3 in a half molar ratio decreased the anti-proliferative 
effect of IFN alpha 2a down to a level of 16.18 % due to a strong masking (neutralizing) of the 
cytokine by the antibody. An exchange of isoleucine to asparagine at position 52 in the heavy 
chain of the 9F3 antibody triggered a reduced masking capability of the antibody, leading to a 
48.17 % interferon mediated induction of cell death. Similar effects were seen by point mutating 
isoleucine to glycine at position 76 of the heavy chain with a cell killing response of 43.53 %. 
Mutations in the complementarity determining region of the light chain showed unwanted effects 
on the masking capabilities of the antibody compared to point mutations in the heavy chain of 
the 9F3 antibody. The exchanges LC_Pos55_Tyr/Ala (63.53 %), LC_Pos73_Tyr/Asp (65.49 %) and 
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LC_Pos119_Met/Arg (63.39 %) in the light chain of the 9F3 antibody triggered a significant loss of 
affinity of the antibody against interferon alpha 2a which resulted in poor or only partial 
inhibition of the cytokine. Due to the insufficient masking capability of antibodies with point 
mutations in the variable domain of the light chain, modifications in the heavy chain of 9F3 were 
preferred to achieve efficient masking of interferon and a possible release of the cytokine at the 
tumor site at the same time.   
Previously described point mutations in the binding region of the anti IFN alpha 2a antibody 9F3 
were additionally evaluated via surface plasmon resonance spectroscopy to determine the 
affinity modulating effect of each attempt (figure 33).  
 
Figure 33: Adaptation of antibody masking intensity 
Binding affinities of modified anti-IFN alpha 2a antibodies were determined by using a Biacore T200 device. Anti-human IgG1 
catching antibodies were immobilized on a CM5 gold coated sensor chip by amine coupling. Modified anti-IFN alpha 2a antibodies 
were loaded on three of the four chambers of the sensor chip. Human interferon alpha 2a was applied to the system in PBS running 
buffer containing 0.05% Tween, at a flow rate of 50 µL / min and a contact time of 180 seconds. After each washing step, the system 
was regenerated with 30 mM MgCl. Gained data were recorded and visualized by using the Biacore T200 evaluation software. 
Presented data were generated under the guidance of Ute Jucknischke, Roche Diagnostics GmbH. 
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The unmodified anti IFN alpha 2a antibody 9F3, developed by Genentech Inc., exhibits an affinity 
to human wild type interferon alpha 2a in a range of 25 pM (data were provided by Genentech 
Inc.). Point mutations at position 52 (a) and position 76 (b) in the heavy chain of the antibody 
have triggered a moderate decrease of the affinity to a level of 49 pM (a) and 35 pM (b). Although 
an exchange of methionine to arginine at position 119 in the light chain of the antibody has just 
slightly decreased its affinity down to 41 pM, masking capability of the antibody was completely 
lost (figure 32). An exchange of tyrosine at position 55 to alanine in the variable domain of the 
light chain has led to a reduction of the antibody affinity down to 1.4 nM. Similar effects were 
seen for another amino acid exchange at position 73 of the light chain. The replacement of 
tyrosine by asparagine reduced the affinity of the 9F3 antibody to human interferon alpha 2a to 
1.5 nM and triggered a significant loss of masking capability. 
The intended use of the antibody 9F3 was to prevent increased levels of interferon alpha 2a in the 
body of patients caused by inflammatory diseases. Due to this planned clinical indication, the 
affinity of the antibody was adjusted specifically to interferon alpha 2a. To determine the binding 
capability of the antibody to other natural occurring interferon alpha subtypes and to evaluate its 
masking effect on several members of this family, a screening assay was performed on the 
multiple myeloma cell line U266B1 with interferon alpha subtypes as monotherapy or in 
combination with the anti IFN alpha 2a antibody 9F3 (figure 34). 
 
Results 
 
68 
 
 
Figure 34: Antibody-induced inactivation of IFN alpha subtypes 
The multiple myeloma cell line U266B1 was treated with thirteen natural occurring IFN alpha subtypes at 10.000 IU / mL in 
combination with the anti-IFN alpha 2a antibody 9F3 in a ration of IFN : antibody of 2:1. Masking efficiency was determined by a 
CellTiter-Glo® luminescence assay. Masking effects were evaluated by the detection of interferon activity in combination with the 9F3 
antibody compared to cells treated with IFN as monotherapy. Blotted values and calculated standard deviations are based on three 
replicates. Except treatment of cells with IFN alpha 2a, IFN alpha H2 and universal IFN alpha, screenings were performed in 
collaboration with Guido Werner, Roche Diagnostics GmbH. 
 
Treatment of multiple myeloma cells with different interferon alpha subtypes resulted in various 
levels of anti-proliferative responses. Interferon alpha 2a as monotherapy has led to an inhibition 
of cell growth by 57 %. After addition of the antibody 9F3, the major part of the cytokine was 
bound and pharmacologically inactivated which reduced the inhibitory effect of interferon down 
to 6.7 %. A similar strong inactivation of the cytokine after addition of the 9F3 antibody was seen 
for IFN alpha 2b. In contrast to the strong binding capability of the antibody 9F3 to IFN alpha 2a 
and IFN alpha 2b, no significant inhibitory effects were determined for IFN alpha J1, IFN alpha K, 
IFN alpha 4b, IFN alpha C and IFN alpha WA. Moderate cytokine binding and inhibition of the anti-
proliferative effect by the antibody 9F3 was evaluated for IFN alpha D, IFN alpha F, IFN alpha I and 
universal IFN alpha. The stimulation of U266B1 cells with interferon alpha H2 showed a reduction 
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in cell growth of 68.6 % compared to untreated cells. After addition of the antibody 9F3, the anti-
proliferative potency of IFN alpha H2 was reduced down to 30.7 %. It was seen the anti IFN alpha 
2a antibody 9F3 exhibits a moderate binding affinity to interferon alpha H2 and no further point 
mutations were necessary to adjust the antibody affinity down to a level for efficient masking and 
at the same time maintain a possible release of the cytokine.  
Structure analysis and 3D modelling approaches revealed the three-dimensional structure and 
antigen binding interface of the 9F3 antibody. To evaluate the intensity and the biological effect 
of the masking capability of the 9F3 antibody, the binding ability of the antibody was abolished by 
removing any amino acids with an antigen binding mediating side chain. The generated antibody, 
incapable to bind any antigen, was called a “Nada”- variant (figure 35). 
 
 
Figure 35: CDR burnishing of the anti IFN alpha 2a antibody 9F3 
Three dimensional modelling of the CDR regions of the anti-IFN alpha 2a antibody 9F3 (a) and corresponding binding kinetics to 
interferon alpha 2a. “Nadazeptized” antibody containing multiple modifications of amino acids in the CDR region of the 9F3 antibody 
to prevent recognition and binding of an antigen (b). Binding kinetics were evaluated via a Biacore T200 device as previously 
described.  3 D modelling of biomolecules was conducted by Dr. Guy Georges, Roche Diagnostics GmbH. Results from SPR 
measurements were generated under the guidance of Ute Jucknischke, Roche Diagnostics GmbH. 
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The three dimensional structure of the human anti-interferon alpha 2a antibody 9F3 revealed 
essential amino acids with side chains responsible for interacting with interferon alpha 2a. The 
evaluation of the antibody affinity to its antigen by surface plasmon resonance spectroscopy 
displayed binding events at a concentration of 25 pM. The exchange of amino acids responsible 
for antigen binding to amino acids with non-reactive side chains in the CDR domains of the VH 
and VL domains of the 9F3 antibody triggered a complete loss of the antigen binding capability of 
the newly generated “Nada-antibody”. Surface plasmon resonance spectroscopy showed no 
detectable binding of interferon alpha 2a by the immobilized Nada-antibody. Due to this loss of 
affinity, the Nada-antibody was used in in vitro assays as a negative control with no masking 
capabilities.  
 
 
 
5.5 Effects of a bivalent non-masking anti-interferon antibody 
 
Interferon fusion proteins containing the non-masking Nada antibody and two molecules of 
interferon alpha H2 were manufactured and evaluated on the multiple myeloma cell line U266B1. 
The experiment showed that interferon fused to a non-masking antibody exhibits a more potent 
anti-proliferative effect on U266B1 cells than unfused interferon alpha H2 at an equimolar ratio. 
This effect was additionally confirmed in other multiple myeloma cell lines like RPMI 8226 and 
NCI-H929. To investigate whether the improvement of the anti-proliferative efficacy of the 
unmasked fused interferon was derived from a clustering of IFN receptors, interferon fusion 
proteins based on the non-masking Nada-antibody were pre-incubated with anti-human Fc 
secondary antibodies to crosslink the interferon fusion proteins. After this pre-incubation, the 
multiple myeloma cell line U266B1 was treated with the crosslinked antibodies in serial dilutions 
for 72 hours (figure 36).  
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Figure 36: IFN receptor clustering to explain improved anti-proliferative efficacy 
Cell viability assay of the multiple myeloma cell line U266B1. Bivalent IFN fusion proteins (a) and monovalent IFN fusion proteins (b) 
were applied in serial dilutions to 5000 cells / well in combination with crosslinking secondary antibodies, binding to human IgG1 Fc 
part (green, orange line) or to human IgG1 kappa domain (black line). Crosslinking antibodies were pre-incubated with IFN fusion 
proteins in a ratio of 1:2 for one hour before treatment of the cells. Cell viability was evaluated after 72 hours by using a CellTiter-Glo® 
luminescence assay. Blotted values and calculated standard deviations are based on six replicates. 3 D modelling of biomolecules was 
conducted by Dr. Guy Georges, Roche Diagnostics GmbH. 
 
Treatment of U266B1 cells with non-masking bivalent interferon fusion proteins showed an 
enhanced anti-proliferative potency (IC50 = 0.51 pM) compared to unfused interferon alpha H2 
(IC50 = 1.85 pM). However pre-incubation of interferon fusion proteins with two different anti-
human Fc antibodies or an anti-human LC antibody slightly reduced the anti-proliferative action 
of interferon fusion proteins but still demonstrated an increased inhibitory effect on all growth 
compared to free interferon alpha H2. In contrast to the synergistic effect of bivalent interferon 
fusion proteins, no beneficial effects were seen in case of monovalent fusion proteins. Equimolar 
ratios of interferon alpha H2 (IC50 = 1.85 pM) and a monovalent interferon fusion protein (IC50 = 
9.19 pM) displayed significant differences in the anti-proliferative activity of both stimulants. The 
application of secondary antibodies to crosslink the monovalent interferon fusion proteins did not 
show any improvement in the potency of the monovalent antibody. Due to these results a 
potential explanation for the synergistic effect of bivalent non-masking interferon fusion proteins 
by the crosslinking of IFN receptors on the cell surface was not able to be confirmed. Improved 
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pharmacologic activities of Nada-IFN fusion proteins were not seen in tumor cell lines originating 
from solid tumors (data not shown).   
 
 
5.6 Screening for tumor specific proteases 
 
A key aspect of the proposed interferon fusion protein approach is the selective release of the 
cytokine at the tumor site. Due to the masking effect of the used antibody, interferon stays 
inactivated as long as it is stably fused to the antibody by a peptide linker. After cleavage of the 
linker, interferon is able to diffuse away from the antibody and becomes reactivated at the tumor 
site. To ensure a specific release of the cytokine only in the tumor microenvironment, a peptide 
linker is required which contains a selective cleavage motif for tumor associated proteases. 
During circulation of the fusion protein in the periphery, the peptide linker has to be stable to 
ensure masking and inactivation of interferon for the prevention of unwanted interaction of the 
cytokine in off-target tissue.  
The following section of the thesis summarizes the approach to identify suitable cleavage motifs 
inside the peptide linker which show a high grade of stability in plasma and suitable turn-over 
rates by tumor associated proteases.  
 
 
5.6.1 Peptide linkers specific for matrix metalloproteinases 
 
Matrix metalloporteinases (MMPs) play an import role for the degradation of the extracellular 
matrix of tumors which facilitates the spread of tumors to other tissues and enforces 
metastasization. Due to an overexpression of several subtypes of matrix metalloproteinases in 
cancerous tissue, different substrates and cleavage motifs for MMPs were investigated to be 
incorporated in the peptide linker, connecting interferon to its masking antibody. Results from 
literature search and patent applications have led to a selection of different amino acid 
sequences which are preferentially cleaved by MMP-9 and MMP-2. These two prominent 
representatives of the matrix metalloproteinase family show high similarities for their substrates 
and are expressed at high levels in many tumor types.  
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The amount of enzymatically active MMP-9 and MMP-2 in several tumor lysates was determined 
by zymograms (figure 37, a)) in order to identify suitable in vitro models. Sequences for peptide 
linkers specifically cleaved by MMP-9 and MMP-2 were selected by a literature search (figure 37, 
c)) and incorporated in interferon fusion proteins containing a masking anti-IFN antibody. 
Manufactured interferon fusion proteins were tested on the multiple myeloma cell line U266B1 in 
comparison with a non-cleavable (G4S)6 peptide linker (figure 37, b)). 
 
Figure 37: Matrix metalloproteinase cleavable peptide linker 
Enzymatic activities of MMP- 9 and MMP-2 were determined for several IFN alpha treated and untreated tumor cell line lysates by 
using zymography technology (a). Peptide linker sequences found in literature (c) were incorporated in IFN fusion proteins and 
evaluated on the multiple myeloma cell line U266B1 (b). Cells were seeded at a density of 5000 cells / well and treated with serial 
dilutions of interferon fusion proteins [10nM] for 72 hours. Final readout was performed by a CellTiter-Glo® luminescence assay. 
Blotted values and calculated standard deviations are based on six replicates. Screening of protease activity by zymograms was 
conducted by Ingrid Munk, Roche Diagnostics GmbH. 
 
The evaluation of tumor lysates originating from different tissues by zymograms indicated high 
enzymatic activities of MMP-9 and MMP-2 in the pancreatic cancer cell line BxPC-3 and the 
hepatocellular carcinoma HT1080. Moderate levels of active enzymes were determined in the 
multiple myeloma cell lines U266B1 and RPMI 8226 with a slight majority of MMP-2 activity. 
Additionally active proteases were detected in the estrogen receptor, progesterone receptor and 
Her2 receptor triple negative breast cancer cell lines MDA-MB-468. 
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Treatment of the multiple myeloma cell line U266B1 with serial dilutions of interferon fusion 
proteins containing MMP-specific peptide linkers from literature resulted in diverse turn-over 
rates of the linkers by matrix metalloproteinases depending on the applied sequence. As a 
negative control a fusion protein with a non-cleavable (G4S)6 peptide linker was used with an IC50 
value of 89.04 pM. The application of a peptide linker derived from Turk et al. only slightly 
improved the IC50 value of the fusion protein to 76.2 pM. Higher linker turn-over rates (31.1 pM) 
were determined for a fusion protein containing a S-G-K-G-P-R-Q-I-T-A cleavage motif from Kridel 
et al.. A significant shift in the potency of the masking interferon fusion proteins was achieved by 
the introduction of a MMP-9 specific peptide linker derived from the patent WO 2010/081173A2 
with an IC50 value of 13.37 pM. The highest turn-over rate of a peptide linker was determined for 
the K-G-P-R-S-L-G-K (Fudala et al.) amino acid sequence leading to an IC50 value of the interferon 
fusion protein in the range of 7.46 pM (Fudala et al., 2011; Kridel et al., 2001; Turk, Huang, Piro, & 
Cantley, 2001). 
 
 
5.6.2 Peptide linkers selectively cleaved by matriptase 
 
In addition to the previously described screening for peptide linkers cleaved by matrix 
metalloproteinases another attempt for a tumor specific release of interferon was investigated. 
The group of LeBeau et al. published data for a tumor specific activity of a membrane bound 
serine protease called matriptase. Matriptase is distributed all over the body and occurs also in 
healthy tissues but always in combination with its inhibitor HAI-1. A beneficial characteristic of 
cancerous tissue is the down-regulation of the enzyme inhibitor HAI-1 in contrast to health 
tissues (figure 38, b)). Due to this effect, the protease matriptase occurs only in tumors in its 
enzymatically active form. To utilize this biological effect of tumors, peptide linkers from 
literature (figure 38, a)) were incorporated in interferon fusion proteins which are specifically 
cleaved by active matriptase. Generated fusion proteins were tested on the ovarian cancer cell 
line OVCAR-3 to determine turn-over rates of the applied matriptase specific linker sequences 
and to select a potential candidate for the bispecific masking interferon fusion protein (figure 38, 
c)). 
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Figure 38: Membrane bound serine-protease cleavable peptide linker 
Peptide sequences which contain cleavage motifs for the serine-protease matriptase were gained by literature search and in-house 
modifications of known matriptase substrates (a). Tumor selective occurrence of enzymatically active matriptase was shown by 
LeBeau et al. (b). Interferon fusion proteins containing matriptase cleavable peptide linkers were tested in serial dilutions [10nM] on 
the ovarian cancer cell line OVCAR-3 (c). Cell viability and indirect measurement of linker turnover rates was determined via a 
CellTiter-Glo® luminescence assay. Detected deviations in cell viability compared to untreated cells were blotted and standard 
deviations calculated on the basis of six replicates. 
 
The matriptase specific peptide linker R-Q-R-R-V-V-G-G originating from the MEROPS data base 
showed no significant difference compared to a stable (G4S)6 peptide linker because auf the 
application of a masking interferon fusion protein (9F3) for the R-Q-R-R-V-V-G-G linker in contrast 
to non-masking Nada-variants for other matripase linkers. Additional experiments showed that 
the MEROPS linker was efficiently been cleaved by matriptase (data not shown). An in-house 
developed point mutation of the MEROPS linker to R-Q-R-R-V-V-N-G significantly improved the 
turn-over rate of the linker on the ovarian cancer cell line OVCAR-3 to an IC50 value of 25.1 pM. 
Similar cleavage rates were achieved for fusion proteins containing peptide linkers with sequence 
similarities to the matriptase inhibitor HAI-1 (22.7 pM) or to the matriptase substrate HGF (25.1 
pM).  
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5.6.3 Dual specific tandem linker 
 
From previously performed screening assays, several suitable peptide linker for a specific 
cleavage by the tumor associated proteases MMP-9/2 and matriptase were identified. To 
increase the likelihood of linker cleavages at the tumor site another approach was conducted to 
combine a matriptase specific sequence with a MMP-9 specific sequence in one peptide linker. 
The generated “Tandem Linker” combines the amino acid sequences of the matriptase linker 
derived from the MEROPS database and the sequence for MMP-9 mediated cleavage originating 
from the patent WO 2010/081173A2. On the N- and C-terminus the tandem linker is flanked by 
four glycines and one serine as spacers and located between interferon and the CH1 domain of 
the anti IFN antibody. To determine the cleavage rate of the developed tandem linker, fusion 
proteins were generated containing a matriptase linker, a MMP-9 linker or the tandem linker with 
both sequences and tested on the ovarian cancer cell line OVCAR-3 (figure 39). 
 
Figure 39: Tandem linker with synergistic turnover rate 
The schematic diagram of the antibody heavy chain of the interferon fusion protein visualizes the incorporation site and composition 
of the used peptide tandem linker (a). Enzymatic turnover of the tandem linker in contrast to monospecific MMP linker and matriptase 
linker was evaluated on the ovarian cancer cell line OVCAR-3 (b). Cells were treated with serial dilutions of interferon alpha H2 [20nM] 
or bivalent masking interferon fusion proteins [10nM] which contain previously mentioned linker sequences. Cell viability was 
determined by using a CellTiter-Glo® luminescence assay after treatment duration of 72 hours. Displayed inhibition curves and 
standard deviations were calculated on the basis six replicates. 
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Table 6: IC50 values of fusion proteins containing different peptide linkers 
Peptide linker IC50 [pM] 
Interferon alpha H2 (reference) 37.41 
Tandem linker 44.71 
MMP9/2 linker 350.9 
Matriptase linker 797.9 
 
Treatment of OVCAR-3 cells with human interferon alpha H2 resulted in a maximum induction of 
cell death of 85% with an IC50 value of 37.41 pM. In the presented experiment, unfused 
interferon alpha H2 was used as reference for 100 % turnover rate of the peptide linker. A 
masking interferon fusion protein containing a monospecific matriptase cleavable linker achieved 
a maximum anti-proliferative effect of 62.6 % and an IC50 value of 797.9 pM. A significant 
improvement of the linker turnover rate was seen by the application of a MMP-9 selective 
peptide linker in the masking interferon fusion protein with an increased maximum effect of 72.6 
% and an IC50 value of 350.9 pM. The combination of both sequences of the MMP-9 linker and 
the matriptase linker in one tandem linker resulted in a reduction of the IC50 value down to 44.71 
pM and a maximum induction of cell death of 76.9 % which indicates a >90 % turnover rate of the 
tandem linker compared to monospecific peptide linkers. 
 
Used peptide linkers for the interferon fusion protein have to be not only cleaved efficiently by 
tumor associated proteases, but also show a high grade of stability during circulation in the 
periphery. To determine the plasma stability of the previously described peptide linkers, fusion 
proteins with each of the protease specific linker were incubated in murine plasma for 24 hours 
at 37 °C (figure 40). 
 
Figure 40: Plasma stability of protease cleavable linkers 
Stability of MMP-, matriptase- and tandem linkers in murine plasma was evaluated by Western Blot. Corresponding interferon fusion 
proteins were incubated for 24 hours in murine plasma at 37 °C and 300 rpm shaking mode. After a recovery step by magnetic protein-
A beads, SDS gel electrophoresis was performed and gained protein bands blotted on a PVDF membrane. Antibody heavy chains 
containing a non-cleaved linker (75 kDa) or with a cleaved linker (50 kDa) were marked by an overnight incubation with an anti-human 
IgG1 Fc specific (Fab)2 fragment fused to horse radish peroxidase (HRP). Luminescence signal was gained by the addition of 
LumiLight™ Western Blot substrate and detected by using a Lumi-Imager™ device. 
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Control groups of protein-A beads incubated in PBS or mouse plasma did not show any detectable 
residues from the bead surface on the blot. For the interferon fusion protein containing a tandem 
protease linker, a small amount of cleaved linkers (  ̴20 %) and a majority of non-cleaved peptide 
linker (  ̴ 80 %) was detected in samples incubated in PBS. Fusion proteins containing a stable 
(G4S)6 peptide linker showed only traces of cleaved constructs and more than 99 % of non-cleaved 
linkers (75 kDa) after incubation in mouse plasma. Used MMP-9 and matriptase specific linker 
peptides showed a high degree of plasma stability with similar amounts of cleaved products (lane 
6 and lane 7). The comparison of detected antibody heavy chains of lane 3 and lane 5 revealed a 
moderate plasma stability of the tandem linker. After 24 hours incubation in mouse plasma, half 
of the tested fusion proteins were unspecifically cleaved by murine proteases in the plasma. 
Although the presented tandem linker showed significantly improved turnover rates on several 
cancer cell lines, plasma stability was reduced compared to monospecific peptide linkers.  
 
 
5.7 Manufacturing and evaluation of the interferon fusion protein lead 
molecule 
 
Previously described optimizations of each component of the proposed interferon fusion protein 
were combined in one lead molecule. The interferon fusion protein is composed out of a point 
mutated interferon alpha H2 which is fused to a heavy chain of the masking anti-IFN antibody by 
a tandem protease linker. Second half of the bispecific fusion protein is made out of an anti-
CD138 targeting moiety which ensures the enrichment of the interferon fusion protein at the 
target site. 
The transmembrane heparin sulfate proteoglycan CD138 (Syndecan-1) is a member of the 
syndecan protein family which is up-regulated in many multiple myeloma cancer types (figure 19) 
(O’Connell, Pinkus, & Pinkus, 2004). Due to the tumor selective overexpression of the 
transmembrane protein, an anti-CD138 targeting moiety was chosen as targeting component of 
the bispecific interferon fusion protein for clinical indications in multiple myeloma treatment.  
Results 
 
79 
 
 
Figure 41: CD138 (Syndecan-1) expression in multiple myeloma cell lines 
CD138 expression data were evaluated by RNA sequencing technology originating from Chugai Pharmaceutical Co., Ltd. a 
member of the Roche Group. 
 
 
 
5.7.1 Purification of the bispecific interferon fusion protein 
 
Seven days post transfection, fusion proteins were harvest from the HEK293F culture by 
centrifugation. Protein A affinity and size exclusion chromatography was used to purify the 
supernatants and separate aggregates from the monomeric fraction (figure 42). 
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Figure 42: Manufacturing and purification of the bispecific interferon fusion protein 
Chromatogram of a protein A affinity chromatography of the bispecific CD138 targeted interferon fusion protein (a). Fusion proteins 
were trapped by using a HiTrap™ MabSelect Xtra™ (flow rate = 1mL/min) and eluted by a citrate buffer (pH3) induced pH shift. For size 
exclusion chromatography (b) of the fusion protein, a HiLoad™ 16/600 Superdex™ 200pg column was applied. Gained protein pool 
from affinity chromatography step was separated by using His-NaCl running buffer (pH6) at a flow rate of 1 mL/min. Protein fractions 
containing monomeric fusion proteins were collected manually.  
 
The protein A chromatogram from the detected UV absorbance at 280nm displayed a rising peak 
after eight milliliter elution volume with a maximum height of 3000 mAU. After 10.5 mL elution 
volume the peak declined and reached the base level after 12.5 mL eluent. The chromatogram 
from size exclusion chromatography showed a peak from 48 to 58 mL with a height of 611.2 mAU 
indicating aggregates of the interferon fusion protein. The second peak from 58 to 75 mL elution 
volume displays the monomeric fraction of the bispecific interferon fusion protein with a 
maximum height of 1733.1 mAU. Determination of the protein concentration of the collected 
monomeric fraction revealed a total amount of interferon fusion protein of 12.3 mg of the non-
cleavable fusion protein and 16.7 mg of the cleavable fusion protein out of one liter of HEK293F 
expression culture. 
To evaluate the correct composition of the purified bispecific interferon fusion protein out four 
different antibody chains, a SDS gel electrophoresis was performed and proteins bands visualized 
by simply blue staining (figure43). 
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Figure 43: SDS gel electrophoresis of the IFN antibody conjugate 
SDS gel electrophoresis to control correct assembly of the bispecific interferon fusion protein was conducted by applying 20 µL of a) 
non-reduced protein pools and b) reduced protein pools,  on to each lane of NuPage® 4-12% Bis-Tris Gel. c) Sample loading scheme for 
each gel. Electrophoresis was performed at 230 V for 35 minutes. Separated protein bands were visualized by SimpleBlue staining 
solution. Determination of protein fraction size was determined by comparison with the defined Precision Plus Protein Marker. 
 
On the gel with non-reduced samples from protein purification steps, protein bands could be 
observed in the eluate from protein A chromatography (lane 4), the aggregate fraction from size 
exclusion chromatography (lane 5) and the monomeric fraction of the bispecific interferon fusion 
protein (lane 6) with a molecular weight of 190 kDa which correlates with the calculated 
molecular weight of the fusion protein. Under reduced conditions (gel b)) protein bands were 
stained at 75 kDa which indicates interferon fused to one heavy chain of the fusion protein. 
Additional bands were found at 50 kDa which represent the unfused CD138 targeting arm of the 
fusion protein. Light chains corresponding to both arms of the interferon fusion proteins were 
detected at 25 kDa without any separation of both chains due to the identical molecular weight. 
 
 
5.7.2 Functionality of the CD138 targeting moiety 
 
The transmembrane proteoglycan CD138 was selected as target for the interferon fusion protein 
due to its overexpression in several multiple myeloma cell lines. To evaluate the functionality of 
the targeting moiety of the generated bispecific interferon fusion protein, different cell lines were 
incubated with fluorescence labeled fusion proteins. Live cell imaging of the cultures was 
performed by confocal microscopy to determine interactions between the interferon fusion 
protein and tumor cells (figure 44). 
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Figure 44: Confocal microscopy of CD138 targeted IFN fusion proteins 
Anti CD138 targeted bispecific interferon fusion proteins were labelled by using the Mix-n-Stain™ antibody labeling kit (Biotium). 
CD138 positive multiple myeloma cell lines U266B1 and NCI-H929 and the CD138 negative cell line Hela-S3 were incubated with 
labelled fusion protein in the corresponding growth medium. Confocal microscopy was performed by using an Eclipse TE2000-E, D-
Eclipse C1si LSM microscope (Nikon) after 1h, 8h and 24 hours. Membrane staining and internalization of the fusion protein was 
visualized by Nikon EZ-C1 V.3.80 software. Microscopic analysis of prepared samples was performed by Oliver Tonn, Roche Diagnostics 
GmbH. 
 
The CD138 negative cancer cell line HelaS3 did not show an enrichment of the fluorescence 
labelled interferon fusion protein on the surface of the cell nor aggregations of internalized fusion 
proteins in any compartment of the cells. Co-cultivation of CD138 positive NCI-H929 multiple 
myeloma cells with labelled interferon fusion proteins resulted in strong immobilization of the 
fusion protein on the surface of the cells already after one hour. Intensity of membrane staining 
of the NCI-H929 cells increased until next measurement after eight hours. After 24 hours, first 
internalized aggregates of the interferon fusion protein were determined in cellular 
compartments which indicates a slow internalization rate of protein at moderate CD138 
expression levels. Results from RNA sequencing experiments (figure  41) indicate that the 
multiple myeloma cell line U266B1 possesses the highest density of CD138 on the cell surface 
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compared to other tumor cell lines from this indication. Already after one hour, U266B1 cells 
showed clear membrane staining by the CD138 targeted interferon fusion protein with high levels 
of internalized fusion proteins. Eight hours post administration, the majority of labelled fusion 
proteins was internalized and aggregated in the cytosol of the cells. Further incubation until 24 
hours showed no difference in membrane staining or the amount of internalized fusion protein 
compared to images taken after eight hours. 
 
5.7.3 Pharmacologic potency of the interferon fusion protein 
 
Subsequent evaluation of the targeting functionality of the interferon fusion protein, the 
pharmacologic potency of the fusion protein was investigated. To determine maximum induction 
of apoptosis and IC50 values of the interferon fusion proteins containing a cleavable tandem 
linker or a non-cleavable (G4S)6 linker, cell viability assays were conducted on the multiple 
myeloma cell line U266B2 over 72 hours (figure 45). 
 
Figure 45: Proof of concept evaluation in multiple myeloma 
Cell viability assay of targeted bispecific interferon fusion proteins containing a protease cleavable linker (red curve) or a non-cleavable 
peptide linker (blue curve) in comparison to human interferon alpha H2 (black curve) and IFN alpha 2a (orange curve) on the multiple 
myeloma cell line U266B1 (a). Schematic diagram of the tested bispecific interferon fusion protein and listing of applied antibody 
modifications (b). Cell viability assay was performed by treating 5000 cells/well with serial dilutions of interferon alpha [20nM] or 
interferon fusion proteins [20nM] for 72 hours. Assay readout was determined by using a CellTiter-Glo® luminescence assay. Blotted 
values and standard deviations were calculated based on six replicates. 3 D modelling of biomolecules was conducted by Dr. Guy 
Georges, Roche Diagnostics GmbH. 
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Table 7: Evaluated IC50 values of proof of concept fusion proteins 
Anti-proliferative compound IC50 [pM] 
FF2_CD138_9F3_tandem linker_IFN-H2_HYNS 1.25 
Interferon alpha H2 1.38 
FF1_CD138_9F3_(G4S)6_IFN-H2_HYNS 16.84 
Interferon alpha 2a 613.2 
 
Treatment of U266B1 cells with serial dilutions of interferon alpha 2a showed a maximum 
apoptotic effect of 82.9 % and a half maximal inhibitory concentration of 613.2 pM. A decrease of 
the required IC50 concentration down to 1.38 pM was achieved by the stimulation of the multiple 
myeloma cells with human interferon alpha H2. Applied dilutions of targeted interferon fusion 
protein containing a non-cleavable linker induced a maximal growth inhibitory effect of 85.3 % at 
an IC50 concentration of 16.84 pM. Compared to interferon alpha H2, the masking effect of the 
fusion proteins triggered an increase in the half maximal inhibitory concentration by more than a 
factor of 12. In contrast to the masking interferon fusion protein with a non-cleavable linker, 
fusion proteins with incorporated protease cleavable tandem linkers achieved 88.3 % induction of 
cell death at a similar IC50 value (1.25 pM) compared to unfused interferon alpha H2 (1.38 pM). 
To confirm the previously presented positive pharmacological effects of the bispecific interferon 
fusion protein to other cell lines and clinical indications, similar cell viability assay were 
performed to the multiple myeloma cell lines RPMI 8226 and NCI-H929 and the ovarian cancer 
cell line OVCAR-3 (figure 46).  
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Figure 46: CD138 targeted IFN in several MM cell lines and ovarian cancer 
Evaluation of the reproducibility of the previously described efficacy of the targeted interferon fusion protein and application of it on 
different cancer cell lines. Multiple myeloma cell lines U266B1 (a), RPMI 8226 (b), NCI-H929 (c) and the ovarian cancer cell line OVCAR-
3 (d) were treated with serial dilutions of interferon fusion proteins [20nM] and human interferon alpha H2 [20nM]. Cell viability was 
determined by CellTiter-Glo® luminescence assay after treatment duration of 72 hours. Blotted inhibition curves and standard 
deviations were calculated on the basis of six replicates. 
Table 8: Similar shifts of IC50 values in different cell lines 
 U266B1 RPMI 8226 NCI-H929 OVCAR-3 
FF2_CD138_9F3_ 
tandem linker_IFN-H2_HYNS 
0.43 1.01 10.59 11.95 
Interferon alpha H2 0.71 1.16 14.26 11.34 
FF1_CD138_9F3_(G4S)6_IFN-H2_HYNS 6.18 11.56 107.7 274.2 
 
 
In the multiple myeloma cell line U266B1, interferon fusion proteins with a non-cleavable peptide 
linker (IC50 = 6.18 pM) displayed an increase of the half maximum inhibitory concentration by 
more than a factor of 14 compared to fusion proteins with an incorporated tandem linker (IC50 
=0.43 pM). A comparable difference between masking non-cleavable (IC50 = 11.56 pM) and 
cleavable (IC50 = 1.01pM) interferon fusion proteins were seen in the RPMI 8226 cell line. 
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Determined dose response curves in the multiple myeloma cell line NCI-H929 displayed same 
effects for the evaluated interferon fusion proteins than in other multiple myeloma cell lines, 
although calculated IC50 values were increased by a factor of 10 due to a decreased interferon 
sensitivity of NCI-H929. Treatment of the ovarian cancer cell line OVCAR-3 resulted in similar dose 
response curves of interferon alpha H2 (IC50 = 11.34 pM) and the interferon fusion protein 
containing a protease cleavable peptide linker (IC50 = 11.95 pM). In contrast to results obtained 
in multiple myeloma cell lines, the masking effect of the non-cleavable fusion protein triggered an 
increase in IC50 values between (G4S)6 and tandem linker by more than a factor of 22. Fusion 
proteins with a non-cleavable linker showed a half maximal inhibitory concentration of 274.2 pM 
in contrast to interferon fusion proteins with an incorporated tandem linker (IC50 = 11.95 pM). 
Interpretations, possible explanations and consequences of the previously described data are 
discussed and explained in further detail in the following section of the thesis.  
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6. Discussion 
 
 
Since the early discovery of interferon by Isaacs and Lindenmann in 1957, extensive work and 
scientific approaches to characterize this cytokine were conducted to reveal its anti-viral and anti-
proliferative potency. Following first promising treatment results in oncologic indications and 
extensive promotions of interferon by the pharmaceutical industry in the early 80s, it quickly 
became clear that the application of this potent cytokine is often accompanied by severe adverse 
side effects. In many instances, interferon-based therapies in several oncologic indications and 
infectious diseases significantly interfere with the patient’s quality of life. Treatment has to be 
interrupted due to unspecific responses of interferon in the body which lead to a diverse set of 
acute and chronic toxicities (Borden et al., 2007; Isaacs & Lindenmann, 1957). 
To address these serious issues and possibly broaden the clinical application of interferon in 
oncology, temporary inhibition of interferon in combination with a tumor selective reactivation of 
the cytokine holds the potential to reduce or even overcome unwanted effects during interferon-
based treatments while the anti-proliferative potential of interferon remains maintained. A 
possible way to achieve this ambitious goal is described in this thesis, dealing with the fusion of 
human interferon alpha to a masking bispecific antibody. Due to a temporary inactivation of the 
cytokine, unspecific interactions during circulation of the fusion protein in the periphery should 
be significantly reduced with beneficial consequences on the toxicity profile of interferon in 
oncologic indications. Besides the masking capability of the proposed interferon fusion protein for 
the improvement of the side effect profile of interferon, tumor specificity of the pharmacologic 
activity of the cytokine is supported by 1. enrichment of the fusion protein at the target site due 
to a second targeting moiety of the antibody and 2. selective release and reactivation of 
interferon in the tumor microenvironment by the cleavage of a connecting peptide linker by 
tumor-associated proteases. The proposed interferon fusion protein may provide a solution to 
overcome current obstacles and limitations in interferon-based treatment strategies and enforce 
an increased clinical application of this potent anti-viral and anti-proliferative cytokine. Combining 
an improvement of the pharmacodynamical attributes of interferon with a reduced toxicity side 
effect profile of the cytokine may contribute to more efficient cancer therapies and significant 
enhancement of patients’ quality of life.  
Keeping this goal in mind, the following section of the thesis deals with the interpretation of data, 
gained during the development and optimization of the proposed interferon fusion protein.  
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6.1 Clinical indications for an interferon fusion protein 
 
Cell viability evaluation after treatment of the cells with IFN alpha 2a, showed diversified anti-
proliferative responses varying between cell lines with different tissue origin and between 
subtypes of the same oncologic indication. Highest response rates to interferon treatment were 
detected in cell lines derived from multiple myeloma patients which indicates a high therapeutic 
effect in haematologic tumor types. Results from a meta-analysis of 17 clinical trials using 
interferon alpha based treatment strategies in multiple myeloma confirm the observed anti-
proliferative effect of interferon on multiple myeloma cells (Fritz & Ludwig, 2000). Although the 
exact mode of action of interferon in multiple myeloma remains unclear, highest treatment 
efficacies were observed for interferon combination therapies with standard chemotherapeutic 
agents (Khoo, Vangsted, Joshua, & Gibson, 2011). In-house experiments showed that stimulation 
of U266B1 and RPMI 8226 multiple myeloma cells with interferon alpha 2a as monotherapy 
resulted in potent induction of cell death in a range of 65 % to 85 %.  
In contrast to the overall potent anti-proliferative effect of IFN on the majority of multiple 
myeloma cell lines, treatment of OPM-2 and KMS-28 BM cells showed an enforced cell growth. A 
possible explanation for the varying anti-proliferative effect of Type I interferons on multiple 
myeloma cell lines was investigated by the group of Taruna Arora (Arora & Jelinek, 1998). 
Observations of expression levels and activations of cell cycle-associated kinases after stimulation 
of cell lines with interferon alpha have led to the assumption that interferon mainly interferes 
with the cell cycle progression of multiple myeloma cells. In the multiple myeloma cell line KAS-
6/1, which showed accelerated cell growth in the presence of interferon, an overexpression of 
cyclin D2 was determined. Cyclin D2 plays a major role in the cell cycle progression from G0/G1 to 
S phase. In contrast to the growth promoting effect of IFN alpha in KAS-6/1, interferon 
stimulation of ANBL-6 cells resulted in a potent induction of cell death. It is presumed that the 
observed anti-proliferative effect of the cytokine is mediated by an overexpression of the kinase 
inhibitor p19(INK4d) which contributes to cell cycle arrest and induction of apoptosis. 
In addition to efficient inhibition of cell growth in multiple myeloma cell lines, interferon 
treatment showed significant induction of cell death in the triple negative (HER2-, estrogen- and 
progesterone receptor negative) breast cancer cell lines MDA-MB-468 and MDA-MB-231. 
According to this observation interferon fusion proteins may be able to be applied in the 
treatment of triple negative breast cancer which represents an attractive oncologic indication for 
new potent therapeutics due to the high medical need in this hormone-independent tumor types. 
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In vitro evaluation of interferon combination therapies on breast cancer cell lines raised the 
assumption that already small amounts of interferon alpha trigger overexpression of oestrogen 
receptors which sensitizes cells to hormone receptor inhibitory small molecules like tamoxifen 
(van den Berg, Leahey, Lynch, Clarke, & Nelson, 1987). Additional investigations of interferon-
mediated induction of apoptosis in breast cancer cells assume the involvement of the interferon 
regulatory factor 1 (IRF-1) in tumor suppression by the activation of cell death-mediating caspases 
(Bouker et al., 2005). 
Regarding approved clinical indications of interferon alpha, additional cell lines originating from 
malignant melanomas were screened for their responsiveness to interferon based cancer 
treatment. Gained data showed moderate growth inhibition of cancer cells in the presence of 
interferon in a range of 18 % to 47 % reduction of viable cells. Although interferon shows just 
minor effects in the treatment of malignant melanoma, it still remains the only therapeutic agent 
which leads to a prolongation of the relapse free period and an improvement of overall survival of 
patients (Hauschild, 2009). Due to the limitation in treatment alternatives, interferon fusion 
proteins with improved pharmacodynamical attributes and reduced toxicity profiles may be able 
to contribute to an increased survival of malignant melanoma patients or even reduce the burden 
of this highly metastatic malady. Summarizing the experimental data gained during the evaluation 
of a diverse set of cancer cell lines according to interferon-mediated cell death, multiple myeloma 
seemed to be the most favourable indication for treatment with an interferon antibody fusion 
protein. According to these findings and the current clinical application of interferon alpha 2a in 
multiple myeloma treatment, the majority of experiments for the development and optimization 
of the proposed cytokine fusion protein was performed on multiple myeloma cell lines. To 
additionally evaluate the interferon fusion protein in solid tumor indications, the ovarian cancer 
cell line OVCAR-3 was used which showed interferon mediated anti-proliferative effects at similar 
levels than the most sensitive multiple myeloma cell line U266B1. 
To determine suitable oncologic indications for an interferon fusion protein experiments were 
performed with human interferon alpha 2a due to its approved clinical application and broad 
knowledge about pharmacokinetic and pharmacodynamic parameters of the cytokine. However, 
other members of the interferon alpha family may also exhibit potent anti-proliferative activities 
in oncologic indications and provide suitable candidates for an interferon fusion protein. 
Treatment of U266B1 cells with all subtypes of the type I interferon family displayed varying 
degrees of cell death induction in the multiple myeloma cell lines. Other interferon alpha 
subtypes such as IFNαB2, IFNαH2, IFNαWA and universal IFN alpha showed significantly higher 
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anti-proliferative response rates compared to the previously applied interferon alpha 2a,. 
According to the determined differences in the cell death inducing capability of interferon alpha 
subtypes, further attempts for the improvement of the anti-proliferative potency of interferon 
alpha were made. 
 
6.2 Improvement of the pharmacological potency of IFN 
 
The comparison of human interferon alpha 2a and interferon alpha H2 in the treatment of 
U266B1 cells displayed major differences in the anti-proliferative effects of the cytokines. 
Although both interferon subtypes achieved similar maximum inductions of cell death, interferon 
alpha H2 showed a reduction in the IC50 concentration by more than a factor of 24 compared 
IFNα2a. Therefore, this effect was further investigated to possibly explain the differential anti-
proliferative activity of interferon subtypes. It is known that all 13 members of the interferon 
alpha family bind to a common Type I interferon receptor and mediate their biological effects by 
the activation of a Jak/STAT signalling pathway (Platanias, 2005). To determine differences in the 
interactions of the cytokines and their receptors, a 3D modelling approach was applied to 
investigate binding moieties of IFNα2a and IFNαH2 to the human interferon receptor. 
Over the past decade several investigations in the field of interferon and its interaction with both 
receptor units IFNAR1 and IFNAR2 were performed. Interferon-induced anti-proliferative effects 
are most likely mediated via the interferon receptor subunit IFNAR1 (Eyal Kalie et al., 2007; 
Piehler et al., 2012). Further experiments to characterize the biological influence of the affinity of 
interferon to subunits of the IFN receptor made clear that besides the affinity of IFN to each of 
the IFNAR subunits, the stability of the ternary complex of IFN and both receptor units plays a 
major role in the potent biological activities of interferon (E. Kalie et al., 2008). Therefore, the 
binding interaction between interferon alpha 2a and the interferon receptor unit IFNAR1 was 
analysed by 3D modelling approaches. The anti-proliferative activity of IFNα2a and IFNαH2 was 
tested by amino acid sequence comparisons of both cytokines. Cristal structure analysis of the IFN 
alpha 2a / IFNAR1 complex revealed a strong contribution of threonine at position 86 of the 
interferon peptide to the binding interaction between the cytokine and IFNAR1. The alignment of 
the amino acid sequences of IFN alpha 2a and IFN alpha H2 showed that IFNαH2 possesses 
isoleucine instead of threonine at position 86 of the peptide chain. The exchange of threonine to 
isoleucine possibly explains the more potent anti-proliferative effect of IFN alpha H2 due to an 
increased hydrophobic interaction of the cytokine with the interferon receptor IFNAR1.   
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The discovery of the affinity mediating and anti-proliferative effect enhancing amino acid at 
position 86 of interferon revealed the possibility for an improvement of the pharmacodynamical 
parameters of the cytokine leading to an enhancement of the anti-proliferative potency of an 
interferon antibody fusion protein. According to data presented by the company Teva GmbH at 
the 6th World ADC Summit 2014 in San Diego, efficient treatment of multiple myeloma would 
require interferon alpha 2a amounts above the maximum tolerable dose (MTD) of the cytokine. In 
more than half of the treated samples, effective interferon alpha 2a doses were 100 to 1000 
times above the MTD. To overcome this limitation of interferon application in multiple myeloma 
treatment and possibly broaden the therapeutic efficacy of the cytokine, the improvement of 
pharmacodynamical attributes of interferon is required. 
First attempts to improve the efficacy of interferon alpha 2a were conducted by the exchange of 
threonine at position 86 by leucine, arginine and histidine. Treatment of the multiple myeloma 
cell line U266B1 with interferon fusion proteins containing point mutated IFN alpha 2a showed 
that the mutation Thr86His efficiently improved the anti-proliferative potency of the cytokine 
compared to wild type IFNα2a due to enhanced hydrophobic interactions of the cytokine and its 
receptor (figure 7). The introduction of arginine instead of threonine at position 86 triggered a 
loss in the maximum induction of cell death and an increase in the necessary half maximum 
inhibitory concentration of the interferon fusion protein. Reduced anti-proliferative effects by the 
Thr86Arg mutation may be explained by sterical hindrances of binding interactions of IFN alpha 
2a and IFNAR1 due to the large unfavourable amino acid side chain of arginine. 
Besides the discovered Thr86His mutation which leads to an increased affinity of interferon alpha 
2a to its receptor, additional work was carried out in the lab of Gideon Schreiber (Eyal Kalie et al., 
2007). A phage display library was established to screen for IFN alpha 2a mutants with enforced 
affinities to IFNAR1 leading to an improvement of the anti-proliferative potency of the cytokine. 
To reach this goal, interferon alpha 2a was randomly mutated at three positions which seemed to 
be involved in the binding interaction to IFNAR1. A mutated variant of human IFN alpha 2a was 
identified which comprised the mutations H57Y, E58N and Q61S (YNS mutations). Further 
characterizations of the YNS variant showed that binding affinity of IFN (YNS) to IFNAR1 was 
increased 60-fold compared to wild type interferon alpha 2a. Binding affinity to the interferon 
receptor unit INFAR2 was not affected. Evaluations of the YNS mutant version of interferon alpha 
2a in vitro displayed a 150-fold improved anti-proliferative effect compared to wild type 
interferon on WISH cells. No significant influence of the YNS mutations on the anti-viral potency 
of the cytokine was determined (Eyal Kalie et al., 2007).  
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Interferon antibody fusion proteins were generated containing wild type IFNα2a, IFNα2a with an 
incorporated Thr86His mutation, an IFNα2a YNS mutant version and interferon alpha 2a with 
both the YNS and Thr86His mutations (HYNS mutation) to evaluate the potency of various IFN 
mutations in this format. Treatment of the ovarian cancer cell line OVCAR-3 with serial dilutions 
of interferon fusion proteins containing the point mutations resulted in clear differences 
regarding the anti-proliferative potency. Compared to wild type interferon alpha 2a, the 
application of the Thr86His mutation reduced the necessary half maximum inhibitory 
concentration by more than half. The in-house and interferon fusion proteins with applied YNS 
mutations showed a reduction in the IC50 value from 613.2 pM of wild type interferon down to 
41.3 pM confirming the data by Schreiber et al. (Eyal Kalie et al., 2007).The combination of YNS 
mutations with the previously in-house discovered Thr86His mutation has triggered an additional 
shift in the IC50 value of the fusion protein down to 24.2 pM (figure 7).  
The 25-fold reduction in the necessary IC50 of the HYNS-mutated interferon fusion protein is 
explained by exchange of four amino acids mainly responsible for the interaction of the cytokine 
to IFNAR1. Since affinities to IFNAR2 are not affected by these mutations, published data were 
confirmed. Following the promising improvements of IFN alpha 2a, Thr86His, YNS and HYNS 
mutations were additionally applied to the IFN alpha H2. Wild type IFN alpha H2 exhibits a 
previously described increased anti-proliferative effect compared to wild type IFN alpha 2a. It was 
hoped to improve even this potent IFN alpha subtype by the application of IFNAR1 affinity-
mediating point mutations. Cell viability assays of U266B1 cells revealed a similar potency of 
fusion protein containing IFN alpha 2a with HYNS mutations or IFN alpha H2 wild type. 
Introduction of HYNS mutations in IFN alpha H2 just slightly improved its anti-proliferative 
potency indicating that the affinity of wild type IFN alpha H2 to IFNAR1 is almost maximized. The 
HYNS mutations of IFNαH2 were able to reduce the IC50 concentration of the fusion protein from 
0.9 pM (wild type IFN alpha H2) to 0.6 pM which identified HYNS mutated IFNαH2 as the most 
potent choice for the proposed masked interferon antibody fusion protein. 
To evaluate the potency of interferon fusion proteins with the incorporated HYNS mutation in 
comparison to standard chemotherapeutic agents, the cell line U266B1 was treated with 
interferon fusion protein, the standard of care proteasome inhibitor bortezomib (Field-Smith, 
Morgan, & Davies, 2006), and additional cytotoxic agents. Comparing the IC50 values of the 
growth inhibition curves of the IFN fusion protein and bortezomib, mutated interferon fusion 
proteins displayed a 1000-fold improved potency compared to standard of care treatment in 
multiple myeloma. These promising results supported the hope/expectation for beneficial 
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application of interferon fusion proteins in this indication to enhance anti-tumor treatment 
efficacy in patients suffering from multiple myeloma. 
Still, the risk of unwanted interactions of interferon in the periphery and aggravation of the side 
effect profile of the cytokine (Jonasch & Haluska, 2001) was potentially increased. Regarding 
these concerns and to overcome the dose-limiting toxicity of interferon, an antibody mediated 
masking approach leading to a temporary inactivation of the cytokine was applied.   
 
6.3 Masking and temporary inhibition of interferon 
 
To overcome in interferon based cancer therapy the limitation by side-effects and possibly 
enhance the biological availability/activity of the cytokine, temporary inhibition of interferon in 
interferon antibody fusion proteins by a masking antibody in combination with a selective 
reactivation of the cytokine in the tumor microenvironment may be able to significantly 
attenuate toxic side effects.  
A related attempt for a temporary inhibition and target selective reactivation of a biomolecule 
was conducted by the group of Donaldson et al. (Donaldson, Kari, Fragoso, Rodeck, & Williams, 
2009). To prevent side effects caused by an unspecific binding of therapeutic antibodies to 
healthy tissue, the group applied a masking approach of the CDR regions of antibodies. Therefore 
the antigen binding domains of antibodies were blocked by small peptides similar to their natural 
antigen. The proposed design concept is comprised of two different antibodies which are fused to 
a blocking peptide, masking the counterpart antibody. As long as the blocking peptides are stably 
fused to the antibodies, both kinds of antibodies stay in a masked and inactive state. After 
enrichment of the dual-antibody-construct at the target site, the linker sequence between the 
antibodies and the masking peptide gets cleaved by target associated proteases. Following the 
cleavage of the peptide linker and the dissociation of the dual-antibody-construct, each of the 
antibodies become reactivated and able to induce its pharmacodynamics activity at the target 
tissue.     
The interferon antibody fusion protein presented in this thesis is based on a monoclonal antibody 
termed 9F3 from the company Genentech Inc. (a member of the Roche Group) and exhibits 
binding affinity against human interferon alpha 2a. First in-house evaluations of the antibody in 
vitro displayed a strong binding of IFNα2a which has led to the inactivation of the cytokine to a 
large extend. Due to the masking of interferon by the antibody, most of its biological activity was 
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lost while it was bound to the antibody. This supports the idea of a temporary inhibition of 
interferon by an antibody to reduce or even prevent side effects of the cytokine (figure 10). 
For the proposed mode of action of the interferon antibody fusion protein release of interferon at 
the tumor site after cleavage of the peptide linker was required and, at the same time, ensuring 
an efficient inactivation of the cytokine when bound by the masking antibody . Due to the high 
affinity of the antibody 9F3 to its antigen interferon alpha 2a in the range of 25 pM, a release of 
the cytokine from the antibody would have been highly unlikely. To address this issue, several 
point mutations in the antigen binding domains of the heavy and light chain of the antibody 9F3 
were applied to reduce its affinity for IFNα2a. This enables slow release of the cytokine after 
cleavage of the stabilizing peptide linker. Incorporated point mutations in the variable domain of 
the light chains caused a tremendous loss of affinity which triggered an insufficient interferon 
masking capability of the antibody (figure 10). In contrast to that, mutations at position 52 and 
position 76 in the peptide chain of the variable domain of the heavy chains induced a moderate 
reduction in the antibody affinity and following this, a suitable binding and masking effect of the 
modified 9F3 antibody against human interferon alpha 2a (figure 10). Due to the adjustment of 
the antigen binding affinity of 9F3, the modified antibody was suitable for an interferon antibody 
fusion protein which exhibits masking and inactivation capability of interferon alpha in 
combination with possible release of the cytokine at the tumor site. 
Antibody affinity modifying effects of the point mutations were additionally confirmed by surface 
plasmon resonance (SPR) spectroscopy (figure 11). Mutations in the variable heavy domain 
slightly reduced the affinity of the wild type 9F3 antibody from 25 pM down to 49 pM (Iso52Asp) 
and 35 pM (Iso76Gly) (figure 11) which resulted in appropriate masking and inhibition of 
interferon (figure 10). Point mutations in the variable domain of the light chain led to a decrease 
in affinity of the antibody to 14 nM (Tyr55Ala) and 15 nM (Tyr73Asp) resulting in a quick release 
of interferon from the antibody (figure 11) and poor masking capability of the antibody (figure 
10). It is still unclear why the incorporated mutation at position 119 in the variable domain of the 
light chain has triggered such significant loss of masking capability of the 9F3 antibody in vitro, 
although SPR measurement displayed only a slight reduction of the affinity down to 41 pM (figure 
11). The observed effect might be explained by the change of the binding affinity of the 9F3 
antibody at interferon alpha 2a due to the incorporated mutation. Further investigations in the 
different binding modes of the wild type 9F3 antibody and its point mutated variant to IFNα2a 
should be conducted by antibody epitope mapping technology which may explain the determined 
effect on the biological function of the cytokine.  
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Due to its specificity against a particular member of the interferon alpha family it was unclear to 
what extend the antibody 9F3 is able to bind and mask other members of the IFN alpha 
subfamily. To address this issue and determine the masking capability of the 9F3 antibody on 
other interferon alpha types, cell viability assays with all 13 natural occurring interferon alpha 
types were performed on the multiple myeloma cell line U266B1 in combination with the 9F3 
antibody (figure 12). As expected, strongest binding and cytokine inhibiting effects were observed 
for the combination of IFN alpha 2a and 9F3 antibodies. According to the innate specificity of the 
antibody, only moderate or poor masking effects were determined for the majority of IFN alpha 
family members. The antibody 9F3 displayed a suitable degree of masking in combination with 
interferon alpha H2, taking into account that reduced affinity supports possible release of the 
cytokine at the tumor site. As previously shown, interferon alpha H2 has a significantly improved 
anti-proliferative potency compared to interferon alpha 2a (figure 4) as well being suitably 
masked by the 9F3 antibody (figure 13) which made this cytokine a potent candidate for the 
interferon fusion protein.   
To characterize the masking and cytokine inactivation capability of the 9F3 antibody compared to 
a non-masking antibody, a human IgG1 antibody was generated without functional CDR regions 
(“Nada”-antibody). Therefore, affinity mediating amino acids of the 9F3 antibody were replaced 
by amino acids (alanine, glycine) with short non-reactive side chains. Due to the exchange of 
affinity mediating amino acids, the modified “Nada” version of the antibody 9F3 was not capable 
to bind interferon alpha 2a anymore which was confirmed by SPR measurement (figure 13). 
Unexpectedly, experiments with bivalent interferon fusion proteins which contained the non-
masking “Nada” antibody on the multiple myeloma cell line U266B1 improved the potency of the 
fusion protein compared to treatment with interferon alpha without antibodies (figure 14). The 
effect was reproducible in U266B1 cells which fostered the suspicion of enhanced anti-
proliferative potency by bivalent non-masked interferon fusion proteins.  
Clustering of interferon receptors on the surface of cells by bivalent fusion proteins triggering 
increased downstream signalling and apoptosis compared to monomeric interferon binding to a 
single IFN alpha receptor might be a possible explanation for this effect. To further investigate 
this assumed mode of action of a “Nada” interferon fusion proteins, multiple myeloma cells were 
treated with a bivalent fusion protein and a monovalent interferon fusion protein with only one 
cytokine fused to the antibody (figure 14). Goal of the experiment was to even increase the 
crosslinking of IFN receptors on the cell by pre-incubating interferon fusion proteins with 
secondary anti-human Fc and anti-human LC antibodies, thus, causing crosslinking of the 
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interferon carrying antibodies. In case of bivalent fusion proteins, a clear improvement in the 
anti-proliferative potency of the construct was determined compared to IFN alpha as single 
agent. However, additional application of crosslinking secondary antibodies did not increase the 
potency of the bivalent “Nada” fusion proteins (figure 14, a)). A similar experiment with 
monovalent interferon fusion proteins showed a significantly decrease of the anti-proliferative 
effect of interferon fusion proteins compared to IFN alpha. Although equimolar amounts of 
interferon alpha and interferon fusion proteins were applied, no beneficial effect of the 
monovalent fusion protein was determined even after crosslinking by secondary antibodies 
(figure 14, b)).  
Improved effects of a bivalent “Nada” interferon fusion protein were not able to be confirmed in 
cell lines from indications other than multiple myeloma which indicates a specific susceptibility of 
these malignant cells for IFN fusion proteins. Due to the fact that the proposed interferon fusion 
protein here in this thesis was the first interferon antibody format in a bivalent fashion, no further 
literature was found which would give hinds for an alternative explanation of the observed 
effects. Open questions still have to be addressed to reveal the extraordinary mode of action of 
bivalent non-masking interferon fusion proteins in multiple myeloma derived cell lines. 
Summarizing the outcomes and investigations of the masking and temporary cytokine inhibition 
approach, it was possible to adjust the affinity of the human anti IFN alpha 2a antibody 9F3 to a 
suitable level for effective masking of interferon in combination with a possible release of the 
cytokine at the tumor site. According to the specificity of the 9F3 against IFN alpha 2a and its 
moderate masking of other interferon alpha subtypes, no further affinity adjustments were 
required for the 9F3 antibody at interferon fusion proteins containing IFN alpha H2. Although 
efficient masking and inactivation capability of the described fusion protein was shown in several 
in vitro evaluation studies, final proof of concept has to be conducted in immune efficient animal 
models to determine the consequence of this approach on a desired reduction of unwanted 
responses and toxic side effects in interferon based cancer treatment. The methodology of 
temporarily inhibiting a cytokine can also be applied to other types of cytokines with restricted 
clinical use due to their innate toxicity profile.  
A short peptide linker was incorporated in the construct which connects the cytokine to the 
variable domain of the heavy chain of the masking antibody to achieve a stable binding and 
masking of interferon during circulation of the fusion protein in the periphery. Due to the close 
proximity of the cytokine and the antibody, a bound conformation of interferon is favoured in 
contrast to a linker-free situation with an equilibrium between bound and non-bound cytokine. 
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Therefore, the selection of a suitable peptide linker between the cytokine and the antibody was 
of high importance to ensure stable masking and inactivation of interferon in the periphery and 
selective release of the cytokine at the tumor. 
 
6.4 Protease cleavable peptide linkers 
 
A key feature of the applied peptide linker between interferon and its masking antibody is the 
incorporated protease cleavage site which provides the possibility for target specific release of 
the cytokine due to the cleavage of the linker by tumor-associated proteases. Cancerous tissue is 
well known for the upregulation of certain types of proteases which are produced by the tumor 
cells for degradation of the extracellular matrix (ECM). The removal or even reduction of 
components of the ECM contributes to eased tissue invasion of cancer cells and enforces 
metastasis/colonization. Regarding this essential feature of tumor cells, many therapeutic 
approaches were conducted with the aim of inhibiting tumor-associated proteases to prevent 
spreading of cancer cells to healthy tissue (Koblinski, Ahram, & Sloane, 2000). 
A subclass of these ECM degrading proteases is made up by the family of matrix 
metalloproteinases (MMPs). The family of MMPs includes more than 21 human proteases with 
different substrate specificities, which are able to cleave and degrade nearly every component of 
the extracellular matrix. According to their structure, MMPs are categorized in five secreted 
forms and three membrane-bound versions. MMPs are expressed and secreted in an inactive 
state called zymogens (pro-MMP). Zymogens are converted to their proteolytically active form by 
a complex mutual crosstalk or by interaction with other subtypes of already activated MMPs. Due 
to the diverse composition of the MMP family, several functions in the degradation of 
components of the ECM, cleavage of cell adhesion proteins like cadherins, and the release of the 
extracellular domain of growth factor receptors (e.g. FGF, HER2/neu and ERBB4) are carried out 
by matrix metalloproteinases (Egeblad & Werb, 2002).  
A common characteristic of most cancer types is the up-regulated expression and activation of 
MMPs which strongly correlates with tumor progression, enforced tumor cell invasion into 
healthy tissue, and poor prognostic outcomes in cancer treatment. Although many steps in tumor 
progression are based on genetic alterations in the genome of cancer cells, the enforced activity 
of MMPs in human cancer is presumably caused by transcriptional variations and not by  
alterations of the MMP genes which is probably mediated by oncogene activity or the loss of 
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tumor suppressor genes (Egeblad & Werb, 2002). Due to a high structural similarity of the 
catalytic domain of different members of the MMP family, different substrates in the ECM can be 
cleaved by more than one specific MMP type which explains disappointing clinical results of MMP 
inhibitors in cancer treatment (Egeblad & Werb, 2002; Kridel et al., 2001).  
Despite the inherent similarity of enzymatic active domains of MMPs, several approaches to 
determine cleavage specificities for distinct subtypes of MMPs were conducted to gain further 
insight into the complex network of MMPs. The two subtypes MMP-9 and MMP-2 came into the 
spotlight of scientific research and several approaches to determine substrate specificities and 
biological functions of both MMPs were investigated. Different methodologies were applied to 
reveal cleavage motives of MMPs. Studies of the enzymatic activity carried out by phage display 
libraries (Kridel et al., 2001), screening technologies based on FRET (förster resonance energy 
transfer) principle (Kridel et al., 2001), and mixture based oriented peptide libraries (Turk et al., 
2001) have helped to identify preferred substrates, favoured amino acids within the cleavage 
motives, and the biological crosstalk of MMPs.  
Although direct targeting and inhibition of MMPs did not show to be effective in cancer therapy 
due to the complex network of proteases with redundant cleavage specificities, tumor-specific 
up-regulation of this protease family delivers the possibility to utilize this cancer-associated 
attribute for other therapeutic approaches such as the tumor-selective drug release mediated by 
the cleavage of linker peptides.   
Based on previously described findings concerning specific MMP substrates and their published 
sequences, several MMP-9- and MMP-2-specific cleavage motives were incorporated into the 
stabilizing peptide linker between interferon and its masking antibody in the interferon fusion 
protein. To determine suitable cell lines for the evaluation of cleavage efficacies of the 
incorporated linkers, several cell lines were screened for their amount of active proteases by 
zymograms (figure 15, a)). As expected, tumor cell lines from solid indications (pancreatic cancer 
cell line BxPC3, fibrosarcoma cells HT1080) displayed increased levels of active MMPs compared 
to tumor cells from hematologic indications. This is due to the engagement of MMPs in 
degradation of the ECM and metastasis of solid tumors. Besides the requirement of MMPs for 
solid tumors, cell lines from the hematologic system such as the multiple myeloma cell line 
U266B1 also displayed proteolytic activity. To determine turnover rates of MMP-specific linker 
sequences in vitro, U266B1 cells were treated with interferon fusion proteins containing cleavable 
linker peptides found in the literature (figure 15, b) and c)). Fusion proteins containing a peptide 
linker derived from Turk et al. displayed only moderate cleavage (difference in IC 50 values) 
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compared to a non-cleavable G4S6 peptide linker. Highly efficient cleavage of the incorporated 
linkers was monitored for interferon fusion proteins with applied peptide sequences from Fudala 
et al. and the patent WO 2010/081173A2. Although the linker sequence V-P-L-S-L-Y-S-G (Fudala et 
al.) displayed highest turnover rates, the MMP-9-specific linker sequence V-H-M-P-L-G-F-L-G-P 
was selected to be implemented in the final interferon antibody fusion protein. This was done 
because of the determined instability of the V-P-L-S-L-Y-S-G linker during expression in cell culture 
and incubation in murine plasma (data not shown). The complexity of the matrix 
metalloproteinase network and inherent cleavage specificities of members of this family is also 
reflected by major differences in the amino acid sequence of the MMP-9 specific peptide linkers. 
Even though the application of MMP-specific peptide linkers for the interferon fusion protein was 
successful, more tumor-associated proteases were searched in literature to obtain an alternative 
strategy for release and reactivation of interferon at the target site. Regarding the functionality of 
many different kinds of proteases in the degradation of the extracellular matrix, another tumor-
associated protease called matriptase was tested. Matriptase, also known by the name MT-SP1, is 
a representative of the family of type II transmembrane serine proteases and mainly expressed by 
epithelial cells which are the origin of the most common type of cancer called carcinomas. Up-
regulation of matriptase was shown in several human tumors, including lung, ovarian, prostate, 
and kidney cancer. Until now, the participation of matriptase in cancer progression is not fully 
understood, although it was shown that this kind of protease mediates the activation of pro-
urokinase, vascular endothelial growth factor receptor 2, and pro- hepatocyte growth factor. Due 
to the previously discovered mode of actions of matriptase, it is assumed that this trypsin-like 
serine protease mainly contributes to tumor growth and the invasion of tumor cells into the 
surrounding tissue (Gao et al., 2013; Uhland, 2006). 
Activity of matriptase in healthy epithelial tissue is tightly down-regulated by its associated 
inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1). Recent studies have shown that 
in some tumors the natural balance of matriptase and its inhibitor HAI-1 is deregulated by the 
down-modulation of HAI-1, resulting in high amounts of proteolytically active matriptase (LeBeau 
et al., 2013). Based on this awareness, the group of LeBeau et al. developed a monoclonal 
antibody which selectively recognizes and binds to the active form of matriptase. Screening with 
tissue sections derived from human colon cancer xenograftes confirmed the tumor-specific 
activation of matriptase in 68 % of all tested primary and metastatic colon carcinoma samples 
(LeBeau et al., 2013). Due to the expression of matriptase on the surface of epithelial cells and 
the selective activity of the protease in malignant tissue, active matriptase seemed to be a 
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suitable biomarker in many oncologic indications, thus, delivering an alternative approach for a 
tumor-selective release of the cytokine from the interferon fusion protein.  
First attempts for the incorporation of a matriptase cleavable peptide linker in the interferon 
fusion protein were based on a common substrate sequence (R-Q-R-R-V-V-G-G) for matriptase 
derived from the MEROPS protease data bank. Further optimization of the common substrate 
sequence was performed by an exchange of arginine to alanine at position P2 (developed by Dr. 
Edgar Voss, Roche Diagnostics GmbH) to enhance the turnover rate of the linker by the protease. 
Determination of the linker cleavage kinetics on the ovarian cancer cell line OVCAR-3 displayed 
similar cleavage rates of linker sequence derived from the MEROPS database and sequences 
which are related to the matriptase inhibitor HAI-1 or its natural substrate HGF (figure 16 c)). The 
comparison of tested peptide linker sequences has fostered the assumption that arginine at 
position P1 of the cleavage site mediates an important function to initiate turnover of the linker 
by matriptase. The addiction of matriptase-mediated cleavage of peptide linkers to arginine at 
position P1 was also confirmed by several groups who screened for selective substrates or 
inhibitory compounds for this type II transmembrane serine protease (Beliveau, Desilets, & Leduc, 
2009; Colombo et al., 2012). 
As described above, several protease cleavable peptide linkers were incorporated into interferon 
antibody fusion proteins with selectivity for the matrix metalloproteinase 9 (MMP-9) or the 
membrane bound type II serine protease matriptase. To further increase the likelihood of 
cleavage of the incorporated peptide linker by tumor-associated proteases, a MMP-9-specific 
substrate sequence was combined with a matripase-cleavable peptide in one linker. The newly 
generated “tandem linker” was flanked by a G4S-spacer at the N-terminus followed by a 
matriptase cleavable linker, a peptide sequence with selectivity for MMP-9 mediated cleavage 
and a G4S-spacer at the C-terminus (figure 17, a)). Following incorporation of the newly 
developed tandem linker in interferon antibody fusion proteins, cleavage kinetics of the linker 
were determined using the ovarian cancer cell line OVCAR-3 and compared to fusion proteins 
containing a monospecific peptide linker (figure 17, b)). Based on the half maximum inhibitory 
concentrations of constructs with a monospecific matriptase linker (797.9 pM) or MMP-9 specific 
linker (350.9 pM), a turnover rate of the dual specific tandem linker was expected in a similar 
range compared to the more potent MMP-9 specific linker. Against all expectations, interferon 
fusion proteins containing a tandem linker displayed a tremendous improved linker cleavage rate 
leading to an IC50 value of 44.71 pM which closely corresponds to the anti-proliferative effect of 
unfused IFN (IC50 = 37.41 pM) measured in the same experiment (figure 17, c)).    
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Until now it is not fully understood how the combination of two protease specific peptide 
sequences in one tandem linker is leading to a synergistic effect in the turnover rate of the linker. 
A possible explanation for the observed effect might be the increased likelihood of the tandem 
linker to get in close proximity to either one or another of the two proteases which are able to 
cleave its amino acid sequence. Additionally to the enforced cleavage likelihood, the combination 
of two different protease cleavable peptides in one linker is leading to a new amino acid 
sequence in the transition zone between both linkers. Due to this effect, the generated tandem 
linker may also be cleaved by unknown proteases with specificities to the amino acid sequence in 
the transition zone of both combined linkers. To investigate the observed synergistic turnover 
effect of a dual protease-specific tandem in closer detail, further experiments have to be 
conducted to reveal the exact mode of action of the peptide. During the development of an 
optimized interferon antibody fusion protein, only one matriptase specific linker was combined 
with one MMP-9-associated linker in a tandem linker. The combination of alternative substrate 
sequences for both applied proteases may answer the question whether this effect is restricted to 
the used amino acid sequences in the performed experiments or whether increased turnover 
rates can be expected by the combination of two linkers, irrespective of their peptide sequence. 
Besides the necessity of a suitable turnover of the peptide linker by tumor-associated proteases, 
a high grade of stability of the linker during circulation of the fusion protein in the periphery was 
required. Incubations of fusion proteins containing protease cleavable linkers in murine plasma 
displayed only low cleavage rates of peptide linkers with single protease specificity (figure 18). In 
contrast to these findings, western blot analysis of interferon fusion proteins with an 
incorporated dual specific tandem linker showed a small fraction of cleaved constructs (50 kDa) in 
samples incubated in PBS and a slight increase of the cleaved fraction over time during incubation 
in mouse plasma (figure 18). According to these findings, it was assumed that the combination of 
both protease cleavable peptides in one linker has negatively affected the overall stability of the 
tandem linker. Decreased stability may correlate with an unspecific cleavage of the new tandem 
linker by proteases originating from murine plasma. The sequence of the applied matriptase 
linker contains two arginine residues in a row, which can serve as a substrate for the protease 
furin leading to an intracellular cleavage of the linker during expression of the fusion protein 
(Thomas, 2002). Possible ways to overcome this limitation would be to combine other matriptase 
substrates with a MMP-9 specific linker or to remove possible cleavage sites for unspecific 
proteases by point mutations of the applied tandem linker. Further combination studies of 
substrates for tumor-associated proteases in one peptide linker and optimizations of the selective 
cleavage of them will provide a deeper insight into the synergistic effect of this approach. 
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Additional findings may also provide a suitable new tandem linker which is able to inhibit 
increased turnover rates at the tumor site in combination with a high grade of stability during 
circulation. 
Extensive efforts in the optimization of the pharmacodynamic properties of human interferon, 
the temporary inhibition of the cytokine in the periphery by antibody-mediated masking and the 
connection of both moieties in one fusion protein by a dual specific protease-cleavable linker 
makes the generation of a potent interferon fusion protein possible which holds the potential to 
improve current interferon based treatment strategies in oncology. In addition to the restriction 
of the anti-proliferative activity of interferon at the tumor site by its local reactivation, a further 
targeting approach was used to force fast clearance of the fusion protein from healthy tissue by 
enriching the construct at the tumor. Due to this targeting attempt further decrease the 
likelihood of unwanted responses of the cytokine in the body are expected which beneficially 
influence patients` quality of life together with increased levels of the pharmacologically active 
cytokine at the tumor site.  
In spite of the complex composition and assembly of the bispecific antibody, several protein 
modelling techniques and amino acid modifications were applied to overcome the hurdles of 
generating this promising fusion protein in high amounts, sufficient for further in vitro 
characterizations and future proof of concept studies in animal models.    
 
6.5 Experiences and findings during manufacturing of a bispecific 
antibody cytokine fusion protein 
 
Planning and manufacturing of a complex molecule like the proposed interferon antibody fusion 
protein with a second binding specificity for a tumor-associated antigen required the application 
of several protein engineering tools to ensure correct pairing of the four different antibody chains 
of the fusion protein. Dimerization of the antibody heavy chain fused to interferon alpha and the 
second heavy chain with a binding specificity to CD138 was enforced by the use of the “knobs into 
holes” technology (Ridgway et al., 1996) which is further described in the method section of the 
thesis. Although homodimerization of two “knob” – heavy chain was prevented due to steric 
hindrances, a minor population of “hole”- heavy chain homodimers could still be detected. To 
circumvent this problem and purify correctly assembled heterodimeric fusion proteins, additional 
HYRF mutations (Natsume et al., 2008) were introduced in the targeting heavy chain of the fusion 
protein. Besides these antibody engineering tools, further techniques like the “CrossMab” 
Discussion 
 
103 
 
technology (Schaefer et al., 2011) and an exchange of charged amino acids in the first constant 
domains of the antibody were made to control the correct pairing of each antibody light chain to 
its corresponding heavy chain (described in more detail in the method section of the thesis). 
Transient expression of bispecific interferon fusion proteins containing previously mentioned 
protein modifications resulted in high amounts of captured molecules by protein A 
chromatography (figure 20, a)). Size exclusion chromatography displayed a moderate fraction of 
aggregated proteins and a majority of monomeric interferon fusion proteins (figure 20, b)). 
Despite the complexity of the bispecific fusion protein, it was possible to gain similar protein 
yields (12 – 17 mg/L) as for unmodified IgG antibodies by transient expression in HEK293F 
suspension culture. Following purification of the fusion proteins, the correct assembly of the 
constructs out of four different antibody chains was confirmed by gel electrophoresis (figure 21). 
Protein bands were detected at 75 kDa corresponding to a heavy chain with fused interferon 
alpha, at 50 kDa standing for heavy chains containing the targeting moiety of the fusion protein 
and at 25 kDa displaying the light chains of the construct. Due to the identical size of the 
interferon masking light chain and the light chain contributing to the targeting moiety of the 
fusion protein, it was not possible to separate both types of antibody light chains by gel 
electrophoresis. To further analyse and confirm the correct assembly of the bispecific interferon 
fusion protein, mass spectroscopy would be an alternative technology to characterize the 
manufactured molecule in more detail. 
With the successful manufacturing and characterization of the targeted interferon fusion protein 
by simultaneous application of several protein engineering tools, sufficient amounts of the 
proposed molecule were generated for further analysis of the expected mode of action of the 
fusion protein and first proof of concept studies in vitro. 
 
6.6 Functional characterization of the proposed interferon fusion protein 
 
Based on the screening results of cancer cell lines derived from different oncologic indications, 
multiple myeloma seemed to be the most promising indication to test the full potential of the 
optimized bispecific interferon fusion protein (figure 1). Therefore, cancer cell lines derived from 
multiple myeloma patients were chosen for first proof of concept studies of the fusion protein. A 
common characteristic of multiple myeloma cells is the overexpression of the transmembrane 
heparin sulfate proteoglycan CD138 also known as syndecan-1. By up-regulation of CD138 mainly 
forcing tumor progression it co-localizes with the VEGF receptor 2 (VEGFR-2) leading to neo-
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angiogenesis in the tumor mass located in the bone marrow (Lamorte et al., 2012). Besides its 
important role in angiogenesis, CD138 mediates additional functions in the tumor survival, cell 
adhesion, and growth of multiple myeloma cells (Dhodapkar et al., 1998). According to other 
data, overexpression of CD138 in multiple myeloma cell lines was also confirmed by mRNA 
expression analysis (figure 19) as shown by the Chugay Pharmaceutical company (a member of 
the Roche group). 
For the evaluation of the tumor targeting functionality of the bispecific interferon fusion proteins, 
cancer cell lines with known CD138 expression levels were selected and treated with 
fluorescence-labelled fusion proteins. Confocal microscopy revealed an intense membrane 
staining of the multiple myeloma (MM) cell lines NCI-H929 (CD138 positive) and U266B1 (CD138 
highly positive) already after one hour incubation with the fusion proteins (figure 22). Due to the 
fast enrichment of the labelled interferon fusion proteins on the surface of MM cells and no 
detectable signals on HelaS3 cells (CD138 negative), targeting of the tumor-associated antigen 
CD138 was able to be confirmed. In contrast to the CD138 moderate expressing cell line NCI-
H929, high amounts of internalized interferon fusion proteins were detected in CD138 
overexpressing U266B1 cells. According to this observation, internalization of the transmembrane 
proteoglycan CD138 seemed to correlate with the level of proteins located on the surface of the 
cells. Similar data on the internalization of CD138 can be found in literature (Fuki et al., 1997), 
although the observed correlation between the protein expression level and the degree and 
speed of internalization of the proteoglycan has not been reported so far. 
Successful targeting of the tumor-associated antigen CD138 by one binding moiety of the 
bispecific interferon fusion protein has further strengthened a proposed suitability of the 
generated fusion protein for a future clinical application in the indication of multiple myeloma. 
Besides the proven enrichment of the construct on the surface of the cells, its pharmacologic 
activity was evaluated by treatment of U266B1 cells with serial dilutions of interferon fusion 
proteins containing a cleavable or a non-cleavable peptide linker between the cytokine and its 
masking antibody (figure 23). Results from the performed experiments display an efficient 
masking and inactivation of the cytokine in case of an applied non-cleavable G4S6 peptide linker 
compared to unfused fully active interferon alpha H2. The increase of the necessary half 
maximum inhibitory concentration (IC50) of cytokines fused to a masking antibody, clearly 
demonstrated a significant neutralization of the pharmacologic activity of interferon mediated by 
the binding of the cytokine by the antibody. In contrast to the strong reduction of the anti-
proliferative activity of interferon in case of constructs with an incorporated non-cleavable linker, 
Discussion 
 
105 
 
interferon fusion proteins with a bispecific protease cleavable tandem linker displayed efficient 
cell killing effects. Due to the similar IC50 concentrations of unfused human IFN alpha H2 and 
interferon fusion proteins containing a tandem linker, a 95 - 100 % turnover rate of the protease 
cleavable linker was reasoned. Gained data verified the proposed mode of action of the targeted 
interferon fusion protein which deals with a targeted enrichment of a temporarily inactivated 
cytokine at the tumor site, followed by reactivation of the cytokine after protease-mediated 
cleavage of the peptide linker between the masking antibody and the cytokine. 
To validate the observed pharmacologic potency of the bispecific fusion protein and prove the 
functionality of the antibody masking approach on a broad basis, additional multiple myeloma 
cell lines and the ovarian cancer cell line OVCAR-3 were treated with non-cleavable fusion 
proteins and constructs with an applied protease-cleavable tandem linker (figure 24). The first 
promising results from cell viability assays in U266B1 cells were could be extended to other 
multiple myeloma cell lines with similar anti-proliferative activities of the cytokine and antibody 
masking efficiencies in a comparable range. In multiple myeloma cell lines the masking ability of 
the applied 9F3 antibody reduced the pharmacologic activity of the cytokine by a factor of 10 - 14 
in contrast to the solid tumor cell line OVCAR-3, were a 23-fold decrease in interferon activity was 
monitored. Based on these findings, it was concluded that cytokine masking and inactivation 
functions of the interferon fusion protein are increased in vitro in adherent cancer cell lines 
derived from solid tumors. This is likely to correlate with a lower accessibility of the tumor cells 
compared to multiple myeloma cell lines in suspension culture. 
Summarizing the obtained results during the complete elaboration and development of the 
targeted interferon fusion protein, it was possible to manufacture a new kind of targeted 
antibody drug conjugated with a presumable application in oncologic personalized health care. 
Enforced anti-proliferative activity of interferon by selective point mutations in combination with 
a reduced side-effect profile due to antibody-mediated temporary inhibition of the cytokine 
might contribute to more efficient cancer therapies and a significant improvement in patients` 
quality of life in future times. 
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7 Outlook and perspectives 
 
 
An inherent genetic instability of the cancer genome and the redundancy in many signalling 
pathways promoting cell growth and survival, challenge treatment strategies in modern cancer 
therapies. Due to these characteristics, growth receptor blockage and pathway inhibition 
approaches often lack clinical efficacy. Recruiting the pleiotropic function of interferon with its 
direct anti-proliferative and immune-stimulatory mode of action in combination with a tumor-
selective activation of the cytokine reveals a new promising attempt in the fight against cancer. 
This might deliver new possibilities to overcome current limitations in targeted treatment 
strategies. 
Promising results gained from first in vitro evaluation studies of the targeted interferon fusion 
protein support the beneficial value of the proposed antibody cytokine conjugate. Despite the 
improved potency of interferon, its efficient masking and targeted delivery by the 9F3 antibody, 
further investigations have to be performed to optimize the plasma stability of the applied 
protease cleavable tandem linker. Therefore, selective point mutations in the sequence of the 
tandem linker or the combination of alternative protease cleavable sequences can lead to a 
reduced turnover of the linker during circulation of the fusion protein in the periphery. Besides 
the optimization of the applied tandem linker, additional questions have to be addressed in vitro 
before further evaluations of the interferon fusion protein in tumor-bearing animal models. 
During the development and optimization of the bispecific interferon fusion protein the main 
focus was set on the anti-proliferative activity of the cytokine. In addition, further experiments 
have to be conducted to reveal the influence of immune co-stimulatory effects of interferon in 
the treatment of cancer. First hints about the function of masked interferon fusion proteins on 
cells of the immune system can be given by NK - cell and CD8+ - T cell activation assays in vitro. 
Based on the outcome of these investigations, it might be possible to show differences between 
wild type interferon and masking interferon antibody conjugates in the activation of immune 
cells. This might foster the argument of a reduced side effect profile of interferon antibody fusion 
proteins.  
Besides the extensive characterization of the interferon fusion protein in vitro, a deeper insight 
into the functionality of the molecule has to be generated by its application in predictive animal 
models. Therefore, sufficient amounts of the interferon fusion protein have to be provided by the 
development of human cell lines stably expressing the recombinant protein. Also, optimization of 
the downstream processing procedure is required to ensure a high grade of purity of the product. 
First in vivo evaluations of the interferon fusion protein in non-tumor bearing mice will help to 
answer the question whether the expected pharmacokinetic attributes of the fusion protein are 
similar to normal IgG antibodies due to the applied IgG1 like framework of the fusion protein with 
a functional Fc part. Based on the determined retention period of the fusion protein in the 
periphery, a further development of a suitable dosing scheme can be conducted. To determine 
the anti-tumor activity of the interferon fusion protein in vivo, subcutaneous xenograft models of 
multiple myeloma cells in immune-deficient mice will be a suitable tool to gain a first impression 
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on the pharmacodynamic property of the molecule. Due to the limitation of a poor cross-
reactivity of human interferon alpha to the murine system, investigations of the functionality of 
the fusion protein in vivo have to be performed in humanized mice models. Such models provide 
a more human-like immune system. Alternatively, surrogate interferon fusion proteins containing 
the species cross-reactive universal Type I interferon might be used. 
Based on the future outcomes of pharmacokinetic and pharmacodynamic studies of the 
interferon fusion protein in murine animal models, ongoing toxicology studies in cynomolgus 
monkeys are conceivable. During pre-clinical evaluation of the fusion protein in vivo, expectations 
were raised to overcome current dose-limiting toxicities of interferon while restoring its anti-
proliferative effect on cancer cells. The newly developed interferon fusion protein might 
represent a new potent candidate for clinical studies in the treatment of multiple myeloma. In 
case of a successful application of interferon fusion proteins in the clinic, the proposed approach 
of temporary inhibiting a cytokine and its tumor-selective reactivation may serve as a platform 
technology to reduce unwanted interactions of alternative potent cytokines which are currently 
limited by severe toxicology profiles. Ongoing pre-clinical and clinical investigations of the 
interferon fusion protein will hopefully confirm beneficial results gained from first in vitro 
evaluations and contribute to a deeper understanding of the potential and the applicability of this 
new attempt in modern targeted cancer therapies. 
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